1 Looking for crumbs in the obesity forest: anti-obesity interventions in the Mexican population. History, 2 and systematic review with Meta-Analysis 3 4 Running title: Anti-obesity interventions in Mexican Population 5 Key words: Anti-obesity agents, abdominal obesity metabolic syndrome, systematic review, Meta-6 analysis, randomized clinical trials, type 2 diabetes (T2D). 7 The Síntevi Group 8 Esperanza M. Garcia-Oropesa<sup>1</sup>†, Yoscelina E. Martinez-Lopez<sup>2</sup>†, Sonia María Ruiz-Cejudo<sup>3, 4</sup>, José 9 Darío Martínez-Ezquerro<sup>3, 5</sup>, Alvaro Diaz-Badillo<sup>6,7</sup>, Carlos Ramirez-Pfeiffer<sup>7</sup>, Alejandra Bustamante-10 Fuentes<sup>8</sup>, Elena B. Lopez-Sosa<sup>9</sup>, Oscar O. Moctezuma-Chavez<sup>10</sup>, Edna J. Nava-Gonzalez<sup>11</sup>, Adriana L. 11 Perales-Torres<sup>12</sup>, Lucia M. Perez-Navarro<sup>13</sup>, Marisol Rosas-Diaz<sup>1</sup>, Kathleen Carter<sup>14</sup>, Beatriz Tapia<sup>15</sup>, 12 Juan C. Lopez-Alvarenga<sup>6,7\*</sup> 13 14 15 1 Laboratorio de Biología Molecular, Unidad Académica Multidisciplinaria Reynosa Aztlán (UAMRA), 16 Universidad Autónoma de Tamaulipas, Reynosa, Tamaulipas, Mexico. 17 2 Programa de Doctorado en Ciencias de la Salud. Universidad Nacional Autónoma de México (UNAM). 18 Mexico City, Mexico. 3 Unidad de Investigación Epidemiológica y en Servicios de Salud, Área Envejecimiento (UIESSAE), 19 20 Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS). Mexico City, Mexico. 21 4 Programa de Maestría y Doctorado en Música, Cognición Musical, UNAM, Mexico City, Mexico. 22 5 Centro de Ciencias de la Complejidad (C3), Universidad Nacional Autónoma de México (UNAM), 23 Mexico City, Mexico. 24 6 Department of Human Genetics. University of Texas Rio Grande Valley. Edinburg, Texas. 25 7 Posgrado Universidad Mexico-Americana del Norte. Reynosa, Tamaulipas, Mexico. 26 8 Escuela de Medicina, Universidad Panamericana. Mexico City, Mexico. 27 9 Cirugía General. Hospital Español. Mexico City. 28 10 Asociación Odontológica Mexicana para la Enseñanza y la Investigación. Mexico City.

- 29 11 Facultad de Salud Pública y Nutrición, Universidad Autónoma de Nuevo León, Monterrey, Nuevo
- 30 León, Mexico.
- 31 12 Laboratorio de Bromatología. Unidad Académica Multidisciplinaria Reynosa Aztlán (UAMRA),
- 32 Universidad Autónoma de Tamaulipas, Reynosa, Tamaulipas, Mexico.
- 33 13 Servicio de Nefrología, Dirección de Investigación, Hospital General de México Dr. Eduardo Liceaga,
- 34 Mexico City.
- 35 14 Research and Education Library of the School of Medicine. Education & Academic Affairs. University
- 36 of Texas Rio Grande Valley. Edinburg, Texas. United States of America.
- 37 15 Faculty Development, Associate Professor, Department of Pediatrics. University of Texas Rio Grande
- 38 Valley. Harlingen. Texas.
- † These authors have contributed equally to this work.
- 41 \*Correspondence:

39

44 45

- 42 Juan C. Lopez-Alvarenga
- 43 <u>juan.lopezalvarenga@utrgv.edu</u>
- Tables in the manuscript: 5
- 47 Figures in the manuscript: 10
- 48 Supplemental tables: 2
- 49 Supplemental figures: 3

**Abstract** 

 Mexicans and Mexican Americans share culture, genetic background, and predisposition for chronic complications associated with obesity and diabetes making imperative efficacious treatments and prevention. Obesity has been treated for centuries focused-on weight loss while other treatments on associated conditions like gout, diabetes (T2D), and hypertriglyceridemia. To date, there is no systematic review that synthetize the origin of obesity clinics in Mexico and the efforts to investigate treatments for obesity tested by randomized clinical trials (RCT).

We conducted systematic searches in Pubmed, Scopus, and Web of Science to retrieve anti-obesity RCT through 2019 and without inferior temporal limit. The systematic review included RCT of anti-obesity treatments in the Mexican adult population, including alternative medicine, pharmacological, nutritional, behavioral, and surgical interventions reporting biometric outcomes such as BMI, weight, waist circumference, triglycerides, glucose, among others. Studies with at least three months of treatment were included in the meta-analysis.

We found 634 entries, after removal of duplicates and screening the studies based on eligibility criteria, we analyzed 43, and 2 multinational-collaborative studies. Most of the national studies have small sample sizes, and the studied strategies do not have replications in the population. The nutrition/behavioral interventions were difficult to blind, and most studies have medium to high risk of bias. Nutritional/behavioral interventions and medications showed effects on BMI, waist circumference, and blood pressure. Simple measures like plain water instead of sweet beverages decrease triglycerides and systolic blood pressure. Participants with obesity and hypertension can have benefic effects with antioxidants, and treatment with insulin increase weight in those with T2D.

The study of obesity in Mexico has been on-going for more than four decades, but the interest on RCT just increased until this millennium, but with small sample sizes and lack of replication. The interventions affect different metabolic syndrome components, which should be analyzed in detail with the population living on the U.S.-Mexico border; therefore, bi-national collaboration is desirable to disentangle the cultural effects on this population's treatment response.

Introduction

Obesity phenotypes have been reproduced in arts and culture since the dawn of humanity. The Venus of Willendorf, made 25 to 30,000 years BCE during the upper Paleolithic and currently exhibited in the Natural History Museum in Vienna, is a figure depicting a woman with abdominal obesity symbolizing femininity, beauty, and fertility. In Mexico the artistic expression in the well-preserved Bonampak, which literally means painted wall, shows the Mayan ruling family of Bonampak, led by King Chaan Muwan and his wife Lady Rabbit (1). The scenes painted between 790 and 792 AD show human figures with signs of overweight or obesity. Other figurines from western Mexico show male abdominal distension, some of them may represent fat, ascites, cancer, or other underlying conditions with controversial significance (2).

For centuries, treatments for obesity have been described, mainly focused on weight loss and as a treatment for other secondary conditions such as gout and diabetes. In Greek and Roman art, obesity generated displeasure and sarcasm, being caricatured as an excess of alimentary and sexual stereotypes. This deviation from the norm was unacceptable in ancient Greek art, and they called by the term "Hippocratic Corpus" what we now call *morbid obesity*. The cause of obesity was considered the excess of fluids circulating in the body, therefore, the treatment consisted of restricting the fluid balance through diet, exercise, and medications. Since then, side effects of treatments have been described, like any leanness of the body causes corrugation of the skin, or if a woman is pregnant there would be risk of miscarriage.(3) The literature brought contrasting characters like Sancho Panza and Don Quixote, or Falstaff and Hamlet, stereotypes from Cervantes and Shakespeare, respectively. This jolly fat figure remains in traditional celebrations like the image of Santa Claus contrasting with slim Scrooge (4).

In the eighteenth-century, the medical literature documented the association of obesity with fatigue, gout, and breathing difficulties. Fat was considered reprehensible and medically undesirable. The progression of nutrition as science with direct calorimetry measurement experiments from Atwater and Benedict (5) between 1898 and 1900 analyzed the law of the conservation of energy applied to living organisms' metabolism. They made a detailed description of demographic characteristics in men, diet, physical activity recorded in their "Metabolism experiments". During the last century Vague (6) described the well-known android and gynecoid morphologies. He measured the perimeter and thickness of adipose tissue with calipers. Obesity has become a recognized clinical entity, subject of research and treatment with medication and behavioral techniques.

- 109 In the United States, Mexican Americans are considered part of the Hispanic Americans or Latino group.
- 110 The U.S.-Mexico border represents this minority with active immigration, and a rapid increase in
- population. One of the Healthy People 2020 goals was to improve the health of all groups, requiring an
- understanding of the Hispanic culture, and health care needs for health promotion (7).

Obesity in Mexico, a story never told

- 116 The Obesity Clinic started in 1959 at the Instituto Nacional de Nutricion Salvador Zubiran, by Dr. Luis
- Domenge, Dr. Carmen Ramos and Dr. Jorge Gonzalez-Barranco. Obesity was considered as an aesthetic
- 118 but also a medical problem. The so-called epidemiologic transition, from infectious to chronic
- degenerative diseases, moved slowly from the 70s and 80s. The evolution of treating obesity as a medical
- problem was promoted by Dr. Gonzalez-Barranco based on scientific research and clinical trials with
- medications in the 90s.

115

- The first attempt to classify obesity was using the Metropolitan Life Insurance Company (MLIC) which
- developed standard tables for "ideal" (MLIC 1942) and then "desirable" weight (MLIC 1959) based on
- the observed association of body weight with mortality. These standard tables were the platform for
- developing the current definition for underweight, normal, overweight, and obese individuals based on the
- body mass index (BMI) cut-offs (8).
- The use of BMI as a reliable measurement started with the NHANES from 1988 to 2016. These studies
- demonstrated the age-adjusted prevalence of obesity in the United States increased progressively: from
- 129 22.9 to 39.6 percent. The main issue of concern in regard to BMI involves the growing obesity epidemic
- and the increasing population with high BMI numbers (9).
- Since 1993 a series of population surveys were conducted systematically in Mexico using the BMI. The
- 132 first National Survey on Chronic Diseases (ENEC from Spanish: Encuesta Nacional de Enfermedades
- 133 Crónicas) highlighted obesity as a national public health problem. The prevalence of obesity in Mexico
- has increased substantially since the 1980s, and currently affects over 30% of the adult population (10).
- 135 The epidemiological transition from undernourishment and infectious diseases to emergent chronic
- diseases were well documented in the ENEC. A sequel of undernourishment in presence of an obesogenic
- environment is homeorrhexis as an adaptive response to undernourishment. Homeorrexis or homeorhesis
- comes from the Greek homós, 'equal'; and rhéxis, 'violent rupture', and refers to regulatory mechanisms
- that allow the body to change from one homeostatic, stable condition to another in a programmed fashion,
- e.g. growth during childhood or the onset of lactation (11). A combination of genetic and socioeconomic
- strata were conditions affecting stature. From North to South Mexico the ENEC data show a decrease in
- stature by expenses of the lower body segment (Figure 1), the sitting height is almost similar across
- 143 regions. The stature can modify body composition despite BMI (12) and can be an indicator of
- socioeconomic inequality (13).
- 145 The First Obesity meeting in Mexico with the NAASO and the Pan-American Endocrine Meetings were
- held in Cancun in 1997. These meetings were a landmark achievement for the study of obesity in Mexico
- with the first NOM (Mexican Official Norm) for obesity management, published in 1998 (14). Since this
- new millennium, there has been a spread of interest in obesity in other hospitals and Mexican states.
- 149 Close collaboration with the Diabetes Division at the University of Texas San Antonio Health Science
- 150 Center (UTSAHSC) and the South Texas Diabetes and Obesity Institute (STDOI) at the UTRGV has
- 151 been done since then.

Importance of gathering scientific literature in Mexico

- Mexican Americans are spread all over the United States, the National Health and Nutrition Examination
- 155 Surveys 1988-1994 showed children aged 4 to 17 years who born abroad had significantly lower
- prevalence of overweight / obesity compared to Mexican American children born in the U.S. (PR = 0.77,
- 95% CI: 0.61, 0.96). In contrast, during 2005-2014, there was no evidence of a difference in overweight /
- obesity at birth (PR = 0.95; 95% CI: 0.84, 1.07) and no differences with newer immigrants (<5 years
- 159 living in the U.S.) compared with those born in the U.S. (15).
- Regarding the diet quality, Yoshida et al., (16) reported age differences in diet quality influenced by
- acculturation (customary adoption of a new culture): older Mexican Americans had higher scores in
- Healthy Eating Index (HEI) indicating a better diet quality. For vegetables, fruits, and proteins, middle-
- aged adults had higher scores compared to young adults. Concerning HEI components, a 1-unit increase
- of acculturation was associated with 10% to 20% lower odds of attaining better scores for vegetables,
- fruits, dairy, sodium, and empty calories in almost all ages.

# Medication research and current anti-obesity guidelines

- Some pharmacokinetics determinants of many drugs depend on the body size; for instance, obesity
- modifies the volume of distribution, and drug clearance, probably due to increased activity of cytochrome
- 170 P450 2E1 and possible modifications on tubular reabsorption (17).
- However, not only biology can explain the variability on losing weight, other factors are associated with
- the feasibility of following medical recommendations affected by cultural environment. The importance
- 173 of lifestyle was defined in early times of weight loss intervention but was debated by the use of
- 174 medication.

153

166

- Numerous international published guidelines for anti-obesity treatment consider the local disparities and
- 176 cultural differences of each geographic region. The management of obesity relies on diverse medical
- specialists, health professionals and government decisions. Primary prevention of obesity is fundamental
- and requires policies for favoring spaces for physical activity and a healthy environment. Harmonization
- on treatment cannot be global but can help to tailor weight loss treatments, and metabolic improvement
- 180 for prevention of complications.
- Since 2000 guidelines from the former North American Association for Study of Obesity (nowadays The
- Obesity Society -TOS) and the NIH Working Group were mainly based on dietary therapy, physical
- activity, and behavior therapy, and guided on the appropriate use of pharmacological and surgical
- interventions. The weight loss recommendation was for patients with BMI >30 and those with BMI
- between 25 and less than 30 with two or more complications. They suggested that pharmacotherapy
- should be used only in the context of a treatment program with diet, physical activity, and behavior
- therapy. Once the guide was published, only two drugs were approved for weight loss, sibutramine and
- 188 orlistat (18).

The European guidelines also made emphasis on lifestyle modifications including nutrition and physical activity. The goals are risk reduction (even with modest weight loss i.e. 5-10% of initial body weight), attention on waist circumference and management of complications. They increase the number of drug treatments for obesity approved by FDA (Food and Drug Administration) and EMA (European Medicines orlistat, lorcaserin (only for FDA), phentermine/topiramate (only for FDA), bupropion/naltrexone and liraglutide. They recommend drug discontinuation if the patient does not reach 5% loss of initial weight after 12 weeks of treatment. This guide discusses metabolic surgery focusing on metabolic effects as primary outcomes instead being limited to weight loss (19).

The Endocrine Society in 2015 published the guideline for pharmacological management of obesity (20) implementing diet, exercise, and behavioral modification and suggesting drugs may amplify adherence to behavior change, especially for patients with a clinical history of failure in non-medication treatments.

The nutritional health status in Mexico was affected by government policies, the first supermarket chains selling American processed food in Mexico started in the 1940s. The government eliminated the subsidy of corn tortillas in 1999 with the objective to improve competitiveness in the global economy. This action loaded in closedown local tortilla factories not able to compete. The transition epidemiology from infectious to chronic diseases was rampant in this period. In 2008 the import tariffs on maize, bean, sugar, and mill were eliminated. In response to the nutritional problems and increase in obesity, in 2010 the Ministries of Public Education and of Health published the General Guidelines for Dispensing or Distribution of Foods and Beverages at School Food Establishments (SFEs). After a mass media campaign to reduce consumption of high caloric food, the Mexican congress, in 2014, excised a tax on high energy dense food (21).

This study aims to perform a systematic review with meta-analysis to synthesize and evaluate the evidence of anti-obesity treatments performed in Mexican adults with overweight and obesity. These treatments can include pharmaceutical, behavioral, surgical, nutritional, and alternative interventions designed as controlled clinical trials, to compare results within and between interventions, and finally, to discuss these findings with Mexican American studies.

Methods

216

217

218

235

236237238

239

240

241

242

243

244

245

246247

248

249

- Protocol registration and search strategy
- 219 The protocol was registered in PROSPERO on 11/17/2020 and assigned the registry number
- 220 CRD42020221436. The search strategies included Pubmed, Scopus, and Web of Science databases to
- 221 obtain published literature up to 2019 to include randomized controlled clinical trials for obesity
- 222 conducted in Mexico. To identify additional studies and gray literature, we contacted Medical Societies
- such as the Endocrinology Society from Mexico and researchers from academic institutions such as
- 224 UNAM. For inclusion in the meta-analysis, all interventions had to be conducted for at least three months
- and report both baseline and final BMI. The query was focused on all interventions with overweight or
- obese participants who underwent weight loss treatment. We included nutritional/behavioral treatments,
- with knowledge that many of these interventions cannot be blinded, therefore we assessed the possibility
- 228 of bias using the Grading of Recommendations Assessment, Development and Evaluation (GRADE)
- approach (22). Medications, alternative medicine and surgical interventions were included in the review
- finished in December 2020.
- An example of a search strategy performed in Pubmed without time period limits:
- 232 (("obesity"[MeSH Terms] OR "obesity"[All Fields]) AND ("therapy"[Subheading] OR "therapy"[All
- Fields OR "treatment" [All Fields OR "therapeutics" [MeSH Terms OR "therapeutics" [All Fields]))
- AND ("mexico" [MeSH Terms] OR "mexico" [All Fields]) AND Clinical Trial [ptyp]

# Eligibility criteria

The systematic review included Mexican adult overweight or obese participants in controlled clinical trials subjected to pharmaceutical, behavioral, surgical, nutritional, or alternative interventions. Weight loss was the primary or secondary outcomes. We included studies published in English or Spanish at any time, conducted in Mexican centers and multicentric international studies with Mexican participants. For inclusion in the meta-analysis, treatments had to be conducted for at least three months and indicate baseline and final BMI. When available, we analyzed metabolic syndrome components (i.e., serum concentration of glucose, HDL-C, triglycerides, systolic and diastolic blood pressure, and waist circumference). We followed these criteria for the articles' peer-screening and conducted a third final group review to resolve disagreements. We contacted the corresponding authors to clarify doubts and obtain additional information when necessary.

## Studies selection

- We recovered 634 studies from three databases: Pubmed (n=180), Scopus (n=238), and Web of Science
- 251 (n=216). After eliminating duplicate studies and applying the eligibility criteria, 589 studies were
- eliminated. The flux of the analyzed studies is described in Figure 2. Of the 45 included studies data were

extracted using the Cochrane tool and quality assessed with the Jadad scale. There were 45 studies included in the qualitative synthesis and 25 in the meta-analysis. Of the studies included in the qualitative synthesis, 55 interventions were described: 25 with medications, 27 with nutrition and exercise, and 3 with surgical treatment (Table 1).

# Data extraction process

253

254

255

256

257

258 259 260

261

262

263

264

265

266

267

268

269

270

271

272 273

274

275

276

277

278

279

280

281

282

283

284 285 286

287

288

289

290

291

292

293

The data extraction from the studies was done, by a team of 13 researchers, with a modified Cochrane tool for data collection form to obtain detailed information: type of intervention (drug, nutritional programs, behavioral treatments, use of drugs, surgical interventions or alternative medicine), age of intervention (childhood, adult), duration of treatments, year of the study development, sample size, groups of intervention, blindness of the treatment and the size of effects obtained in each study (Cohen's d). Data extraction was performed in duplicate, and cases of discrepancy were re-analyzed in groups of 4 investigators. When it was necessary, authors were contacted to collect additional information. The main outcome was related with the reduction of BMI, waist circumference or percentage of body fat and biochemical parameters such as glucose, total cholesterol, triglycerides, HDL-c, blood pressure, HOMA-IR and Matsuda. WE used meta-regression to analyze the source of heterogeneity with mean age, mean BMI, location of the study (represented as latitude of the city of recruitment), sex distribution, and duration of the study. Adverse effects were also analyzed.

The quality assessment of the studies was done using the Jadad scale (23) and the risk of bias was assessed with GRADE checklist (22) with the following assessment guidelines:

Low risk studies were treatment with unpredictable allocation: A central office for allocation by phone, web, and pharmacy. Use of sequentially numbered, sealed, opaque envelopes. The drug containers are sequentially numbered and identical. Meanwhile high risk is predictable allocation, like staff know the random sequence in advance. Another high risk of bias was the use of envelopes or packaging without safeguards or non-random, predictable sequence. The attrition bias can be considered if there was a poor description on how much data was missing from each group, or the lack of reasons for missing data and how they were considered in the analysis. We were also interested in whether researchers used intention to treat analysis, imputation of missing values, or just per protocol analysis.

# Statistical analysis

The obtaining of sample size, means, and standard deviation was done with the data from the included studies. The summary of contrast was computed with Cohen's-d differences. All models were analyzed with Restricted maximum likelihood (REML) random effects models, and the pooled effects were described with 95% confidence intervals. Heterogeneity was assessed with I^2 statistics, and we use meta-regression to analyze the heterogeneity. These statistical analyses were conducted with Stata 16.0 (StataCorp, College Station TX).

The network meta-analysis was computed for studies with medication only, because the designs of nutrition/behavior studies did not allow us to build nets. The analysis was performed with Stata 16.0 and

294

295

296

CINeMA to define the network geometry, and effects comparisons. We did not have enough samples of studies to perform a rankogram.

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

Results We collected 634 studies from databases and after duplicate removal identified 64 controlled clinical trials from PubMed, 27 from Scopus and 15 from Web of Science conducted in Mexico. Studies characteristics We included 45 anti-obesity national and multinational collaborative controlled clinical trials involving overweight and obese Mexican adults (>18 yr) subjected to distinct weight-loss interventions: pharmaceutical (25 studies), nutrition and behavioral (15 studies), surgical (2 studies), and alternative (3 studies) interventions (Table 1). Overall interventions included exclusively women were 15, men 5, and both sexes 35. Participant cities Considering 45 interventions from 25 studies used in the quantitative analysis, Mexico City had the highest frequency of studies 38% (n=17), followed by Guadalajara 29% (n=13). The states close to the U.S. border were three (Nuevo Leon, Tamaulipas and Baja California). The details are described in Table 1. Risk of bias and quality We performed a quality assessment at the intervention level. The Jadad mean value for nutritional/behaviour interventions was 3.6 (min 3, max 5), and for drug treatments was 3.7 (min 2, max 5). The nutrition/behaviour interventions had medium risk of bias (by GRADE) in 95% (n=18/19) and high risk of bias in 5% (n= 1/19). Physical activity was difficult to blind. The use of medication as intervention had very low risk of bias in 32% (n=7/22), medium 55% (n=12/22) and high risk in 14% (n=3/22). No differences in bias were found for intervention including T2D participants (Fisher's exact test = 0.286). Synthesis of results This meta-analysis included data from 2074 participants in nutrition/behaviour interventions and 5086 participants with medication, if we exclude multicentric international studies there were 1525 participants from studies exclusively made in Mexico. The main outcomes from individual studies are described in Tables 2 to 4. The forest plots with the pooled analysis are in Figures 3 to 10. Nutritional/Behaviour interventions The comparisons between active nutrition/behavior interventions with placebo showed improvement for BMI [Cohen-d, 95% CI, Figure 3] 0.2 (0.01, 0.38), waist circumference 0.27 (0.01, 0.53, Figure 4), triglycerides 0.34 (-0.02, 0.71; Figure 5), and systolic blood pressure 0.21 (-0.07, 0.49, Figure 6). The

- lowest heterogeneity was for BMI (I<sup>2</sup>= 41%) and the highest for triglycerides (I<sup>2</sup>= 88%). Only one
- 329 intervention with physical activity showed an effect on BMI (Cohen-d of 0.3), increase on HDL-c
- 330 (Cohen-d 0.16), but with wide confidence intervals. Most of these studies excluded T2D individuals,
- therefore the glucose levels did not show difference between compared groups.
- 332 The addition of adding CBT (goal setting, problem-solving, and stimulus control) to either a low-fat diet
- 333 (21% fat, less than 10% saturated fat, 25% protein, 54% carbohydrates), or a low-carbohydrate diet (27%
- protein, 28% fat, 45% carbohydrate) produced significantly greater short-term weight loss compared with
- diet alone. The use of antioxidants with flavonoids contained in dark chocolate showed favorable changes
- in biochemical parameters (total cholesterol, triglycerides, and LDL-cholesterol level in blood) and
- 337 anthropometrical parameters (waist circumference) the pooled analysis with Cohen-d supported
- additionally loss of BMI and decrease in systolic blood pressure (Figure 6).
- Finally, the avoid of sugar-sweetened beverages (SSB) by water substitution showed positive effect on
- plasma triglycerides, and systolic blood pressure.

## Drug treatments and T2D status

- 342 Drug treatment analyzed studies which involved participants with T2D. The size of effect showed
- 343 improvement on BMI (Figure 7), waist circumference (Figure 8) and glucose (Figure 9) for non-T2D
- individuals compared with patients with T2D. The BMI loss in T2D group had a Cohen-d of 0.24 (0.13,
- 345 0.66) compared with non-T2D loss of 0.53 (0.27, 0.80); the waist circumference was Cohen-d 0.22 (0.72,
- 346 1.16) compared with non-T2D 0.55 (0.03, 1.07); diastolic blood pressure 0.18 (0.3, 1.42) vs 0.87 (0.33,
- 347 2.06), respectively. As expected, the treatment had large effect on glucose lowering for treated T2D
- individuals compared with non-T2D (Cohen-d 0.7 compared with 0.26, respectively).
- 349 Some medications used in Mexico had a large effect on weight reduction (Figures 7 and 8) in participants
- 350 without T2D (Cohen-d about 0.9). For instance, the use of DHA (docosahexanoic acid) 470 or 940 mg
- 351 combined with EPA (eicosapentanoic acid) 580 or 1160 mg, compared with placebo, and the use of two
- different formulations (Formula 1: d-norpseudoephedrine 50 mg, triiodothyronine 75 ug, diazepam 5 mg,
- atropine 0.36 mg, aloin 16.2 mg; and formula 2: d-norpseudoephedrine 50 mg, atropine 0.36 mg, aloin
- 354 16.2 mg.) for 6 months compared with placebo. These medications are not approved for treatment of
- obesity by FDA, and the formulations are not legally available for purchase in the US, however, reports in
- 356 US found thyroid intoxication (70). The effect of liraglutide was between 0.3 to 0.6 including participants
- from international samples. Participants with T2D showed the use of phentermine 15 mg and topiramate
- 358 100 mg had higher effect compared with phentermine 7.5 mg and placebo. There was no replication for
- any of these studies, the Egger test on a random model showed no small study effects on BMI for 18
- intervention on nutrition/behavior (p=0.43), nor for 19 intervention on medication (p=0.22).
- 361 It is interesting that systolic blood pressure was modified by non-pharmacological treatments, meanwhile,
- diastolic blood pressure was modified in non-T2D participants treated with medications (Figure 10).
- 363 From the five analyzed studies with medications, three of them included patients with hypertension. The
- prevalence of hypertension was between 24 to 42%. The blood pressure decreases with weight loss, the
- 365 Trial of Hypertension Prevention had a weight loss intervention arm, resulting in reduction of both,
- 366 systolic and diastolic, measurements (71).

# Study heterogeneity sources

The meta regression analyzed the mean age, BMI, months of treatment, comparison with placebo and geographical location measured by latitude. Those confounders that reached statistical significance for HDL-c serum levels were the duration of the intervention [b=1.07 (se 0.49) p=0.03] and the comparison vs placebo [b=4.4 (se 2.1) p=0.04]. The triglyceride serum levels showed effects from the mean age of the study [b=1.3 (se 0.59) p=0.03] and the geographic location [b= -2.7 (se 1.3) p=0.04]. However, the geographic location was close related with the type of intervention, for example, studies located close to the U.S.-Mexico border used physical activity interventions; meanwhile the South regions used nutritional supplements. The diastolic blood pressure was modified by the BMI [b=-0.49 (se 0.27) p=0.067] and geographical location [b= - 0.9 (se 0.44) p=0.04], however these variables were influenced by the treatment with liraglutide. [Supplemental Figures 1 and 2]

## Network meta-analysis

A network meta-analysis of drug treatments and T2D status was performed for BMI, diastolic blood pressure (DBP), and glucose. The network meta-analysis included direct comparisons constructed with connections between treatments, and indirect comparisons using all possible connections between treatments. All networks had the principles of coherence, transitivity, and consistency. This analysis was not feasible for nutritional/behavior interventions due to the design and the small number of studies. Figure 11 illustrates two networks for studies with T2D patients, examining the efficacy of pharmacological interventions on the studied variables, one network for each comparison between treatments and placebo (Supplemental figure 3 panel A) and with metformin (Supplemental figure 3 panel B). These network diagrams provide a graphical representation of how each intervention connects to any other direct comparisons. Tables 5 (matrix A and B) and Supplemental Tables 1 and 2 detail the complete matrix of results, in which the comparative effects between drugs are shown in terms of differences in means standardized.

The contrast matrix between pharmacological treatments with placebo showed a decrease on BMI by any pharmacological intervention, for instance, DHA 470 mg + EPA 580 mg was 0.816 (CI: 0.049, 1.582); DHA 940 mg + EPA 1160 mg: 0.888 (CI: 0.117, 1.658); Formulation 1: 0.959 (CI: 0.324, 1.593); Formulation 2: 0.944 (CI: 0.301, 1.588); Liraglutide: 0.451 (CI: 0.141, 0.761). On the other hand, the status of T2D consistently supported metformin alone and in combinations were the most effective intervention for reducing BMI compared to insulin: -0.898 (CI: -1.431, -0.366). Regarding glucose, the intervention with insulin was more effective in reducing serum glucose levels compared to metformin: -1.506 (CI: -2.084, -0.928); Glimepiride + metformin: -1.332 (CI: -2.083, -0.581) and Glimepiride: -1.332 (CI: -2.077, -0.587). In summary, the interventions with the greatest contribution to the reduction of DBP were metformin: -0.507 (CI: -0.994, -0.020) compared to Glimepiride + metformin, and Glimepiride: -0.507 (-0.980, -0.033) compared to Glimepiride + metformin. The monotherapy interventions have better effectiveness in DBP compared to double therapies.

# Discussion

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

This systematic review and meta-analysis summarize the existing evidence of weight loss as primary or secondary aims in adult population. Our analysis was limited to randomized clinical studies conducted in Mexico or from international multicentric studies with Mexican participants involving nutrition, behavior, medication, or alternative medicine interventions. Some interventions of interest were compared with another active strategy (medication, behavior, physical activity or any different than placebo), this strategy can blunt the size of effect of the intervention, because the effect of active comparators in metabolic and anthropometric variables. We found that all studied interventions were better than placebo, or better than the selected comparator, and many of the published papers made individual paired contrasts between final and basal values. However, we decided to contrast treatments and reported the size of effects by metabolic syndrome component. With this strategy we had the advantage of computing the effect size over a maneuver the researchers considered the best comparator. The results should be interpreted considering these control groups defined by the researchers.

## Interventions

- The 55 analyzed interventions (from 45 studies) were categorized in nutritional/behavior with a total sample of 1,407 participants; drug interventions in Mexico included 1,134; and multinational
- 420 interventions were additional 1,307 participants (Hispanics); surgical procedures were 72 and alternative
- 421 treatments 235 individuals. We obtained a total of 4,155 participants from these trials.
- The nutritional/behavior strategies included supplemental, flavonoids, manipulation of macronutrient content diets (low fat, low carb, high protein) with caloric restriction, water consumption and physical
- activities. Cognitive behavioral therapy (CBT) combined with low calorie diet showed beneficial effects on BMI and waist circumference; and combined with low fat diet deceased glucose, triglycerides. A
- 426 cardioprotective structured hypocaloric diet is more effective than the CBT approach in reducing
- metabolic syndrome (59). Daily flavonoid-rich chocolate (70% cocoa) intake improves fasting plasma
- glucose levels and insulin resistance parameter (HOMA-IR) and the lipid and glucose metabolism (46).
- The physical activity showed benefic but small and non-significant effects for the analyzed variables, due
- to the lack of enough sample size. Other systematic reviews focused on physical activity showed
- Hispanics had less leisure-time compared with other groups in the U.S., the most common activity was
- walking, but the most significant results were those with moderate to vigorous physical activity (72). It
- 433 will be crucial to increase legislative policies to build environments that increase available opportunities
- for physical activities, particularly for this fast-growing population group.
- Adherence to diet and exercise programs (45 min-60 min/d, 5 days per week) are part of the nutritional/behavioral interventions. Other studies reporting that water consumption habit (2–3 L/day) and
- nutritional/behavioral interventions. Other studies reporting that water consumption habit (2–3 L/day) and partially decreasing sugar-sweetened beverage (SSB) intake of at least 250 kcal/d, with nutritional
- counseling was effective in increasing water intake (69), and additionally reduces cardiometabolic risks of
- drinking or eating less sugar in the diet promoting health benefits, although we found positive effect on

- plasma triglycerides and systolic blood pressure in our analysis, perhaps a consequence of the reduction of the SSB consumption.
- The drug treatment with groups of participants with T2D, showed small effect size on improvement on
- BMI, waist circumference and triglycerides compared with larger effects for non-T2D. The orlistat group
- 444 in T2D showed weight loss (BMI and waist circumference) lower level of glucose, triglycerides, and
- systolic blood pressure. Comparing these findings with other studies made in Mexican Americans living
- in the border shows the difficulty of losing weight with programs on self-management education, but the
- 447 HbA1c improved (73). No medication will overcome unhealthy lifestyles.
- 448 Medication showed a larger size of effects on BMI for combined formulations like orlistat, phentermine
- 449 with topiramate, both approved by regulatory agencies. Other formulations like the combination of
- 450 triiodothyronine with phentermine (non-approved by FDA but approved by COFEPRIS Federal
- 451 Committee for Protection from Sanitary Risks), and combination of DHA and EPA showed effect on
- 452 BMI. The authors of the formulations did not show the result on serum glucose neither reported any
- adverse effect. There was no replication for any of these treatments. We found a couple of sibutramine
- 454 trials. This is a retired medication because the cardiovascular risk was greater than the benefits (74),
- specially for the difficulty to identify patients with silent cardiovascular disease (75).
- Surgical intervention is the most effective treatment for patients with morbid obesity. (76) The percentage
- of body weight loss with this intervention ranges between 33 and 77% in a period of 24 months, thus
- demonstrating its effectiveness (77, 78). However, in our surgical papers, no significant differences were
- found in the percentage of weight loss, this due to the fact that both the intervention group and the control
- 460 group had equivalent surgeries (79). One of the studies compared banded versus unbanded laparoscopic
- 461 roux-en-Y gastric bypass and follow up weight changes for 24 months,(67) in a second analysis no
- differences were found between these procedures after five years of follow up (66).

## Risk of bias

463

464

465

466

467

468

469

470

471

472

473

474

475

476

In general, many of the studied interventions are challenging to blind for obvious reasons. For example, a comparison of nutritional interventions vs. exercise or CBT cannot be blind. However, there is a possibility to blind the evaluators, but no studies explicitly describe this strategy. We found that heterogeneity of the results were partially attributable to basal differences between contrasting groups, for example in the study of Rosado et al.,(51) the diastolic and systolic blood pressure were significantly different between the studied low fat milk groups compared with controls. Some surgical studies for weight loss made in the Instituto de Nutricion Salvador Zubiran in Mexico City blinded the abdominal wall for patients and evaluators when they compared the open abdominal approach versus the laparoscopic method. The risk of bias can be lessened but still can compromise the results of the studies. The difficulty in addressing nutritional or behavioral interventions is manifest in studies analyzing racial/ethnic disparities. Multilevel church-based interventions considering socio-ecological influence

showed a greater impact if they consider program interventions tailored to specific communities.

# 477 Limitations

The most important limitations are the lack of replication studies with the same medications, and the small sample size for most of the studies. There was wide variety in the criteria for selection of the participants (i.e.: some studies had too specific eligibility criteria for sex, age and BMI compared with other studies with wide range of options), and, despite similar genetic background, the participants live in sites embedded in cultural diversity (i.e.: Mexico City's environment problems differ from those in States close to the U.S.-Mexico border). We address a broad question regarding the metabolic syndrome components with important heterogeneity of the studies. We addressed this problem using meta-regression to statistically weight the main confounders across studies and the use of a network meta-analysis to compute the magnitude of contrasts between treatment effects. Due to these limitations the obtention of unstable coefficients is possible, therefore, the analysis should be repeated in the future with a greater number of studies.

- The small sample sizes from many of the included studies resulted in low statistical power for contrasting between treatment, and the lack of replication studies increased the standard error for the analysis. The new medications approved by FDA have been tested scarcely in Mexican population. About 44% of the studies were performed in the limit time of placebo effects (about 12 weeks), but those with more time showed effects on the HDL cholesterol levels.
- Future new and replication studies should consider larger periods for treatments to reduce placebo effects.

  Future reviews and meta-analysis should analyze anti-obesity interventions in children and adolescents as
  well old age populations. These suggestions agree with the Healthy People 2030 recommendation on
  study effective strategies to diminish obesity in children and adolescents (80).
  - The Mexican states conducted research in anti-obesity interventions were ten from 32 states. The U.S.-Mexico border has sister states: California-Baja California, Arizona-Sonora, New Mexico-Chihuahua, Texas with Chihuahua, Coahuila, Nuevo Leon and Tamaulipas. The Binational initiative should improve the collaborative studies in the U.S.-Mexico border to address interventions in this population. The programs from this initiative addresses environmental protection, communication committees in particular communities (81). The U.S.-Mexico Border Health Commission has agreements with the Secretary of Health from both countries, and this agency supports initiatives in health security (82). The programs include prevention and wellness using guidelines for eating healthy, physical activity, and of drug misuse and abuse prevention.

## Conclusions

Since 1996, anti-obesity interventions have been conducted in Mexico in randomized controlled clinical studies, mainly focused on pharmaceutical, nutritional, or physical activity interventions. Adult participants included in these studies were predominantly from the central and northern Mexican states, with a clear absence from the costal and southern states. Anti-obesity studies in the Mexican population include small samples and reduced time for interventions. A strategy to improve the statistical power for the studies is to conduct multicentric studies, and a compromise for the State or private industries to provide sufficient finantial resources.

A national web of research is feasible for answering relevant questions regarding anti-obesity interventions and its metabolic consequences. It is clear that not all metabolic syndrome components have the same response to the intervention. The inclusion of Mexican Americans and Mexican immigrants living in the U.S. would be desirable to clarify the importance of different techniques to tackle this problem.

Acknowledgement

We thanks Dr. Victoria Valles from the National Institute of Medical Sciences and Nutrition Dr. Salvador Zubiran (INCMNSZ) for the share of invaluable experience about the ENEC-93. Last, we would like to pay our gratitude and our respects to Dr. Gonzalez-Barranco. He was a pioneer in obesity research since 1970s, Dr. Gonzalez-Barranco passed away in December of 2020.

Funding

# References

531

532

- 535 1. Finegold A. Dramatic Renditions: Battle Murals and the Struggle for Elite Legitimacy in Epiclassic Mesoamerica: Columbia University; 2012.
- 537 2. DeSmet P. Figurines with distended abdomen from ancient Western Mexico2020 January 5th, 538 2021]. Available from: https://www.academia.edu/Documents/in/Pre-Columbian Art
- 539 3. Christopoulou-Aletra H, Papavramidou N. Methods used by the hippocratic physicians for weight reduction. World J Surg. 2004;28(5):513-7.
- 541 4. Eknoyan G. A history of obesity, or how what was good became ugly and then bad. Adv Chronic 542 Kidney Dis. 2006;13(4):421-7.
- 543 5. Atwater WOB, F. G. . Experiments on the metabolism of matter and energy in the human body.
- In: USDA Office of Experiment Stations B, editor. Washington DC: Government Printing Office; 1902. p. 150.
- 546 6. Vague J. Sexual differentiation. A determinant factor of the forms of obesity. 1947. Obes Res. 1996;4(2):201-3.
- 548 7. Services USDoHaH. Healthy People 2020: United States Department of Health and Human
- 549 Services, Washington, DC; 2010 [Available from: https://www.healthypeople.gov/2020/About-Healthy-550 People.
- 8. Komaroff M. For Researchers on Obesity: Historical Review of Extra Body Weight Definitions. J
   Obes. 2016;2016:2460285.
- Weir CB, Jan A. BMI Classification Percentile And Cut Off Points. StatPearls. Treasure Island
   (FL)2020.
- 555 10. Rtveladze K, Marsh T, Barquera S, Sanchez Romero LM, Levy D, Melendez G, et al. Obesity prevalence in Mexico: impact on health and economic burden. Public Health Nutr. 2014;17(1):233-9.
- 557 11. Kondrup J. Basic concepts in nutrition: Energy and protein balance. e-SPEN, the European e-558 Journal of Clinical Nutrition and Metabolism [Internet]. 2008; 3:[e117-e20 pp.].
- 559 12. Lopez-Alvarenga JC, Montesinos-Cabrera RA, Velazquez-Alva C, Gonzalez-Barranco J. Short stature is related to high body fat composition despite body mass index in a Mexican population. Arch
- Med Res. 2003;34(2):137-40.
- 562 13. Castro-Porras LV, Rojas-Russell ME, Aedo-Santos A, Wynne-Bannister EG, Lopez-Cervantes
- M. Stature in adults as an indicator of socioeconomic inequalities in Mexico. Rev Panam Salud Publica.
   2018;42:e29.
- 565 14. Salud Sd. NORMA OFICIAL MEXICANA NOM-174-SSA1-1998, PARA EL MANEJO
   566 INTEGRAL DE LA OBESIDAD. 1998.
- Maldonado LE, Albrecht SS. Does the Immigrant Advantage in Overweight/Obesity Persist over
   Time in Mexican American Youth? NHANES 1988-1994 to 2005-2014. Obesity (Silver Spring).
- 569 2018;26(6):1057-62.
- 570 16. Yoshida Y, Scribner R, Chen L, Broyles S, Phillippi S, Tseng TS. Role of Age and Acculturation
- 571 in Diet Quality Among Mexican Americans Findings From the National Health and Nutrition
- 572 Examination Survey, 1999-2012. Prev Chronic Dis. 2017;14:E59.
- 573 17. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in
- 574 humans. Clin Pharmacokinet. 2010;49(2):71-87.
- 575 18. Initiative NOE. The practical guide. Identification, evaluation, and treatment of overweight and
- obesity in adults. NIH publication Number 00-4084. 2000.
- 577 19. Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, et al. European Guidelines for
- Obesity Management in Adults. Obes Facts. 2015;8(6):402-24.

- 579 20. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al.
- 580 Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin
- 581 Endocrinol Metab. 2015;100(2):342-62.
- 582 21. Ehara T. Mexico and its obesity epidemic. Global Food Cultures [Internet]. 2018. Available from:
- 583 https://wp.nyu.edu/steinhardt-gfcmexico2018/2018/04/11/mexico-and-its-obesity-epidemic/.
- 584 22. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to
- aid consistency and reproducibility of GRADE assessments: development and pilot validation. Syst Rev.
- 586 2014;3:82.
- 587 23. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the
- quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-
- 589 12.
- 590 24. Gonzalez-Heredia T, Hernandez-Corona DM, Gonzalez-Ortiz M, Martinez-Abundis E. Effect of
- 591 Linagliptin Versus Metformin on Glycemic Variability in Patients with Impaired Glucose Tolerance.
- 592 Diabetes Technol Ther. 2017;19(8):471-5.
- 593 25. Gonzalez-Ortiz M, Martinez-Abundis E, Hernandez-Corona DM, Ramirez-Rodriguez AM. Effect
- of tadalafil administration on insulin secretion and insulin sensitivity in obese men. Acta Clin Belg.
- 595 2017;72(5):326-30.
- 596 26. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of
- 597 liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with
- prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-409.
- 599 27. O'Neil PM, Garvey WT, Gonzalez-Campoy JM, Mora P, Ortiz RV, Guerrero G, et al. Effects of
- 600 Liraglutide 3.0 Mg on Weight and Risk Factors in Hispanic Versus Non-Hipanic Populations: Subgroup
- Analysis from Scale Randomized Trials. Endocr Pract. 2016;22(11):1277-87.
- 602 28. Sanchez-Rodriguez MA, Zacarias-Flores M, Castrejon-Delgado L, Ruiz-Rodriguez AK,
- 603 Mendoza-Nunez VM. Effects of Hormone Therapy on Oxidative Stress in Postmenopausal Women with
- Metabolic Syndrome. Int J Mol Sci. 2016;17(9).
- 605 29. Sanchez-Munoz V, Salas-Romero R, Del Villar-Morales A, Martinez-Coria E, Pegueros-Perez A,
- Franco-Sanchez JG. [Decrease of liver fat content by aerobic exercise or metformin therapy in overweight or obese women]. Rev Invest Clin. 2013;65(4):307-17.
- 608 30. Gonzalez-Acevedo O, Hernandez-Sierra JF, Salazar-Martinez A, Mandeville PB, Valadez-
- 609 Castillo FJ, De La Cruz-Mendoza E, et al. [Effect of Omega 3 fatty acids on body female obese
- 610 composition]. Arch Latinoam Nutr. 2013;63(3):224-31.
- 611 31. Martínez-Abundis E, Valera-Gonzalez I, Hernandez-Salazar E, Gonzalez-Ortiz M. Effect of
- metformin and sibutramine on insulin sensitivity and adiposity in obese patients. Obesity and
- 613 Metabolism. 2010;6:100-4.
- 614 32. Meaney E, Vela A, Samaniego V, Meaney A, Asbun J, Zempoalteca JC, et al. Metformin, arterial
- 615 function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp
- 616 Pharmacol Physiol. 2008;35(8):895-903.
- 617 33. Gonzalez-Ortiz M, Martinez-Abundis E, Kam-Ramos AM, Hernandez-Salazar E, Ramos-Zavala
- MG. Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients.
- 619 Cardiovasc Drugs Ther. 2006;20(2):143-6.
- 620 34. Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, et al. X-PERT: weight reduction
- with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to
- treatment predicts weight maintenance. Diabetes Obes Metab. 2005;7(6):699-708.
- 623 35. Zaragoza RM, Lonngi, G., Ortiz, R.A., Huerta, D.R. Comparison of two formulations of d-
- 624 norpseudoephedrine and placebo in obese patients treated during six months [Comparación de dos
- formulaciones de d-norpseudoefedrina y placebo en pacientes obesos tratados durante seis meses]. Med
- 626 Int Mex. 2001:17:260-71.
- 627 36. Cuellar GE, Ruiz AM, Monsalve MC, Berber A. Six-month treatment of obesity with sibutramine
- 628 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res.
- 629 2000;8(1):71-82.

- 630 37. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine
- 631 for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord. 2000;24(2):144-632
- 633 38. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. Second phase of a double-blind study
- 634 clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after 635 treatment cross-over. Int J Obes Relat Metab Disord. 2001;25(5):741-7.
- 636 39. Ramos-Zavala MG, Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA, Gonzalez-
- 637 Lopez R, Santiago-Hernandez NJ. Effect of diacerein on insulin secretion and metabolic control in drug-
- 638 naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care. 2011;34(7):1591-4.
- 639 Fanghanel G, Silva U, Sanchez-Reyes L, Sisson D, Sotres D, Torres EM. Effects of metformin on 640 fibrinogen levels in obese patients with type 2 diabetes. Rev Invest Clin. 1998;50(5):389-94.
- 641 Fanghanel G, Sanchez-Reyes L, Trujillo C, Sotres D, Espinosa-Campos J. Metformin's effects on
- 642 glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care.
- 643 1996;19(11):1185-9.
- 644 Villar MM, Martinez-Abundis E, Preciado-Marquez RO, Gonzalez-Ortiz M. Effect of diacerein
- 645 as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. Arch 646 Endocrinol Metab. 2017;61(2):188-92.
- 647 A. H-B. Phentermine and topiramato vs phentermine plus placebo in patients with overweight or
- 648 obesity class I or II [Fentermina v topiramato contra fentermina más placebo en pacientes con sobrepeso u 649 obesidad clase I o II]. Med Int Mex. 2015;31:125-36.
- 650 Gonzalez-Ortiz M. Martinez-Abundis E. Grupo para el Tratamiento de la Diabetes Mellitus con
- 651 C. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in
- 652 patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy]. Rev 653 Invest Clin. 2004;56(3):327-33.
- 654 Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, et al. Latin-American trial
- 655 of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes 656 Metab. 2003;5(3):180-8.
- 657 Levva-Soto A, Chavez-Santoscov RA, Lara-Jacobo LR, Chavez-Santoscov AV, Gonzalez-
- 658 Cobian LN. Daily Consumption of Chocolate Rich in Flavonoids Decreases Cellular Genotoxicity and
- 659 Improves Biochemical Parameters of Lipid and Glucose Metabolism. Molecules. 2018;23(9).
- 660 Padilla-Camberos E, Barragan-Alvarez CP, Diaz-Martinez NE, Rathod V, Flores-Fernandez JM.
- 661 Effects of Agave fructans (Agave tequilana Weber var. azul) on Body Fat and Serum Lipids in Obesity.
- 662 Plant Foods Hum Nutr. 2018;73(1):34-9.
- 663 Hernandez-Corona DM, Martinez-Abundis E, Gonzalez-Ortiz M. Effect of fucoidan
- 664 administration on insulin secretion and insulin resistance in overweight or obese adults. J Med Food.
- 665 2014;17(7):830-2.
- 666 Martinez-Abundis E, Gonzalez-Ortiz M, Mercado-Sesma AR, Reynoso-von-Drateln C, Moreno-49.
- 667 Andrade A. Effect of avocado soybean unsaponifiables on insulin secretion and insulin sensitivity in 668 patients with obesity. Obes Facts. 2013;6(5):443-8.
- 669 Tovar AR, Caamano Mdel C, Garcia-Padilla S, Garcia OP, Duarte MA, Rosado JL. The inclusion 50.
- 670 of a partial meal replacement with or without inulin to a calorie restricted diet contributes to reach
- 671 recommended intakes of micronutrients and decrease plasma triglycerides: a randomized clinical trial in
- 672 obese Mexican women. Nutr J. 2012;11:44.
- 673 Rosado JL, Garcia OP, Ronquillo D, Hervert-Hernandez D, Caamano Mdel C, Martinez G, et al.
- 674 Intake of milk with added micronutrients increases the effectiveness of an energy-restricted diet to reduce
- 675 body weight: a randomized controlled clinical trial in Mexican women. J Am Diet Assoc.
- 676 2011;111(10):1507-16.
- 677 Hernandez-Gonzalez SO, Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA.
- 678 Chitosan improves insulin sensitivity as determined by the euglycemic-hyperinsulinemic clamp technique
- 679 in obese subjects. Nutr Res. 2010;30(6):392-5.

- 680 53. Ble-Castillo JL, Aparicio-Trapala MA, Francisco-Luria MU, Cordova-Uscanga R, Rodriguez-
- Hernandez A, Mendez JD, et al. Effects of native banana starch supplementation on body weight and
- insulin sensitivity in obese type 2 diabetics. Int J Environ Res Public Health. 2010;7(5):1953-62.
- 683 54. Gomez-Garcia A, Hernandez-Salazar E, Gonzalez-Ortiz M, Martinez-Abundis E. [Effect of oral
- zinc administration on insulin sensitivity, leptin and androgens in obese males]. Rev Med Chil.
- 685 2006;134(3):279-84.
- 686 55. Campos-Nonato I, Hernandez L, Barquera S. Effect of a High-Protein Diet versus Standard-
- Protein Diet on Weight Loss and Biomarkers of Metabolic Syndrome: A Randomized Clinical Trial. Obes Facts. 2017;10(3):238-51.
- 689 56. de Jesus Romero-Prado MM, Curiel-Beltran JA, Miramontes-Espino MV, Cardona-Munoz EG,
- Rios-Arellano A, Balam-Salazar LB. Dietary flavonoids added to pharmacological antihypertensive
- therapy are effective in improving blood pressure. Basic Clin Pharmacol Toxicol. 2015;117(1):57-64.
- 692 57. Rodriguez-Hernandez H, Cervantes-Huerta M, Rodriguez-Moran M, Guerrero-Romero F.
- Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet. Ann Hepatol. 2011;10(4):486-92.
- 695 58. Madero M, Arriaga JC, Jalal D, Rivard C, McFann K, Perez-Mendez O, et al. The effect of two
- energy-restricted diets, a low-fructose diet versus a moderate natural fructose diet, on weight loss and
- metabolic syndrome parameters: a randomized controlled trial. Metabolism. 2011;60(11):1551-9.
- 698 59. Perichart-Perera O, Balas-Nakash M, Munoz-Manrique C, Legorreta-Legorreta J, Rodriguez-
- 699 Cano A, Mier-Cabrera J, et al. Structured hypocaloric diet is more effective than behavioral therapy in
- reducing metabolic syndrome in Mexican postmenopausal women: a randomized controlled trial.
- 701 Menopause. 2014;21(7):711-20.
- 702 60. Macias-Cervantes MH, Rodriguez-Soto JM, Uribarri J, Diaz-Cisneros FJ, Cai W, Garay-Sevilla
- ME. Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in adult overweight men. Nutrition. 2015;31(3):446-51.
- 705 61. Rodriguez-Hernandez H, Morales-Amaya UA, Rosales-Valdez R, Rivera-Hinojosa F, Rodriguez-
- Moran M, Guerrero-Romero F. Adding cognitive behavioural treatment to either low-carbohydrate or
- low-fat diets: differential short-term effects. Br J Nutr. 2009;102(12):1847-53.
- 708 62. Moran S, Uribe M, Prado ME, de la Mora G, Munoz RM, Perez MF, et al. [Effects of fiber
- administration in the prevention of gallstones in obese patients on a reducing diet. A clinical trial]. Rev
- 710 Gastroenterol Mex. 1997;62(4):266-72.
- 711 63. Garcia-Vivas JM, Galaviz-Hernandez C, Becerril-Chavez F, Lozano-Rodriguez F, Zamorano-
- Carrillo A, Lopez-Camarillo C, et al. Acupoint catgut embedding therapy with moxibustion reduces the risk of diabetes in obese women. J Res Med Sci. 2014;19(7):610-6.
- 714 64. Hernandez-Lepe MA, Wall-Medrano A, Lopez-Diaz JA, Juarez-Oropeza MA, Hernandez-Torres
- 715 RP, Ramos-Jimenez A. Hypolipidemic Effect of Arthrospira (Spirulina) maxima Supplementation and a
- Systematic Physical Exercise Program in Overweight and Obese Men: A Double-Blind, Randomized, and
   Crossover Controlled Trial. Mar Drugs. 2019;17(5).
- 718 65. Alvarado-Reynoso B, Ambriz-Tututi M. Effects of repetitive transcranial magnetic stimulation in
- 719 combination with a low-carbohydrate diet in overweight or obese patients. A randomized controlled trial.
- 720 Obesity Medicine. 2019;14:100095.
- 721 66. Zarate X, Arceo-Olaiz R, Montalvo Hernandez J, Garcia-Garcia E, Pablo Pantoja J, Herrera MF.
- 722 Long-term results of a randomized trial comparing banded versus standard laparoscopic Roux-en-Y
- 723 gastric bypass. Surg Obes Relat Dis. 2013;9(3):395-7.
- 724 67. Arceo-Olaiz R, Espana-Gomez MN, Montalvo-Hernandez J, Velazquez-Fernandez D, Pantoja JP,
- Herrera MF. Maximal weight loss after banded and unbanded laparoscopic Roux-en-Y gastric bypass: a
- randomized controlled trial. Surg Obes Relat Dis. 2008;4(4):507-11.
- 727 68. Robles-Cervantes JA, Martinez-Abundis E, Gonzalez-Ortiz M, Cardenas-Camarena L.
- Hernandez-Salazar E, Olvera-Ozuna R. Behavior of insulin sensitivity and its relation to leptin and tumor
- necrosis factor-alpha in obese women undergoing liposuction: 6-month follow-up. Obes Surg.
- 730 2007;17(9):1242-7.

- 731 69. Hernandez-Cordero S, Barquera S, Rodriguez-Ramirez S, Villanueva-Borbolla MA, Gonzalez de
- 732 Cossio T, Dommarco JR, et al. Substituting water for sugar-sweetened beverages reduces circulating
- triglycerides and the prevalence of metabolic syndrome in obese but not in overweight Mexican women
- 734 in a randomized controlled trial. J Nutr. 2014;144(11):1742-52.
- 735 70. Cantrell L. Redotex(R) revisited: intentional overdose with an illegal weight loss product. J
- 736 Emerg Med. 2012;43(2):e147-8.
- 737 71. The effects of nonpharmacologic interventions on blood pressure of persons with high normal
- levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA. 1992;267(9):1213-20.
- 739 72. Loya JC. Systematic Review of Physical Activity Interventions in Hispanic Adults. Hisp Health 740 Care Int. 2018;16(4):174-88.
- 741 73. Brown SA, Garcia AA, Kouzekanani K, Hanis CL. Culturally competent diabetes self-
- management education for Mexican Americans: the Starr County border health initiative. Diabetes Care.
- 743 2002;25(2):259-68.
- 744 74. Williams G. Withdrawal of sibutramine in Europe. BMJ. 2010;340:c824.
- 745 75. Curfman GD, Morrissey S, Drazen JM. Sibutramine--another flawed diet pill. N Engl J Med.
- 746 2010;363(10):972-4.

- 747 76. Peterli R, Wolnerhanssen BK, Peters T, Vetter D, Kroll D, Borbely Y, et al. Effect of
- 748 Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients
- 749 With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. JAMA. 2018;319(3):255-65.
- 750 77. Buchwald JN, McGlennon TW. Systematic review and meta-analysis of medium-
- term outcomes after banded Roux-en-Y gastric bypass. Obes Surg. 2014;24(9):1536-51.
- 752 78. Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N
- 753 Engl J Med. 2017;376(15):1492.
- 754 79. Stanford FC, Alfaris N, Gomez G, Ricks ET, Shukla AP, Corey KE, et al. The utility of weight
- loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study.
- 756 Surg Obes Relat Dis. 2017;13(3):491-500.
- 757 80. Promotion OoDPaH. Overweight and Obesity 2020 [January 11, 2021]. Available from:
- https://health.gov/healthypeople/objectives-and-data/browse-objectives/overweight-and-obesity.
- 759 81. Agency USEP. What is Border 2020? 2020 [updated September 1, 2020January 4, 2021].
- Available from: https://www.epa.gov/usmexicoborder/what-border-2020.
- 761 82. Services USDoHH. U.S.-Mexico Border Health Commission 2020 [Available from:
- 762 https://www.hhs.gov/about/agencies/oga/about-oga/what-we-do/international-relations-
- 763 division/americas/border-health-commission/index.html.

Figure Legends

766

767 768

769

770

771

772

773 774

775

776

783 784

785

786

787

788

789

796 797

798

799

800

801

802

- Figure 1. Height measurement standing up, sitting and the lower body segment. From North to South the height is lower at expenses to the lower segment of the body (p < 0.0001 adjusted by Bonferroni for all regions). The sitting height reflects the upper segment body and shows small differences between regions. Mean and standard deviations. Data obtained from the ENEC 1993. CDMX: Mexico City, Sitting: sitting height, Lower: Lower segment of the body (Height-sitting height).
- Figure 2. Procedure of the study. The flowchart shows the processes of collection, screening, quality assessment data extraction and analysis.
- 777 Figure 3. Pooled analysis of weighted size of effect by Cohen-d in BMI loss with nutritional and behavior 778 interventions. The analysis was stratified by placebo or active comparator. LFDT: Low fat diet, LCD: 779 Low carbohydrate diet, CBT: Cognitive-behavior therapy, Phys Act: Physical activity, Dark Choc: Dark 780 chocolate, AGE: Advance glycation end-product, Hipocal: Hypocaloric diet, WEP: Water and Education 781 Provision, LFM: Low fat milk, Micronut: Micronutrients, PMR: Partial meal replacement, AntiBP: 782 Antihypertensive medication. REML: Restricted maximum likelihood.
  - Figure 4. Pooled analysis of weighted size of effect by Cohen-d in waist circumference with nutritional and behavior interventions. The analysis was stratified by placebo or active comparator. LFDT: Low fat diet, LCD: Low carbohydrate diet, CBT: Cognitive-behavior therapy, Phys Act: Physical activity, Dark Choc: Dark chocolate, AGE: Advance glycation end-product, Hipocal: Hypocaloric diet, LFM: Low fat milk, Micronut: Micronutrients, PMR: Partial meal replacement. REML: Restricted maximum likelihood.
- 790 Figure 5. Pooled analysis of weighted size of effect by Cohen-d in triglycerides serum concentration with 791 nutritional and behavior interventions. The analysis was stratified by placebo or active comparator. 792 LFDT: Low fat diet, LCD: Low carbohydrate diet, CBT: Cognitive-behavior therapy, Phys Act: Physical 793 activity, Dark Choc: Dark chocolate, AGE: Advance glycation end-product, Hipocal: Hypocaloric diet, 794 WEP: Water and Education Provision, LFM: Low fat milk, Micronut: Micronutrients, PMR: Partial meal 795 replacement, AntiBP: Antihypertensive medication. REML: Restricted maximum likelihood.
  - Figure 6. Pooled analysis of weighted size of effect by Cohen-d in systolic blood pressure with nutritional and behavior interventions. The analysis was stratified by placebo or active comparator. LCD: Low carbohydrate diet, CBT: Cognitive-behavior therapy, Phys Act: Physical activity, Dark Choc: Dark chocolate, AGE: Advance glycation end-product, Hipocal: Hypocaloric diet, WEP: Water and Education Provision, LFM: Low fat milk, Micronut: Micronutrients, AntiBP: Antihypertensive medication. REML: Restricted maximum likelihood.
- 803 Figure 7. Pooled analysis of weighted size of effect by Cohen-d in BMI loss with drug (medication) 804 treatment. The analysis was stratified by T2D status. The Form1 and Form2 are described in the text, they 805 are not approved by FDA. Met: Merformin, Sibut: Sibutramine, DHA: Docosahexaenoic acid, EPA:
- 806 Eicosapentanoic acid, Orlit: Orlistat, Glim: Glimepiride, Phent: Phentermine, Top: Topiramate. REML:
- 807 Restricted maximum likelihood.

Figure 8. Pooled analysis of weighted size of effect by Cohen-d in waist circumference with drug (medication) treatment. The analysis was stratified by T2D status. The Form1 and Form2 are described in the text, they are not approved by FDA. Met: Merformin, Sibut: Sibutramine, DHA: Docosahexaenoic acid, EPA: Eicosapentanoic acid, Orlit: Orlistat, Glim: Glimepiride, Phent: Phentermine, Top:

Topiramate. REML: Restricted maximum likelihood.

Figure 9. Pooled analysis of weighted size of effect by Cohen-d in glucose serum concentration with drug (medication) treatment. The analysis was stratified by T2D status. Met: Merformin, Orlit: Orlistat, Glim: Glimepiride, Phent: Phentermine, Top: Topiramate. REML: Restricted maximum likelihood.

Figure 10. Pooled analysis of weighted size of effect by Cohen-d in diastolic blood pressure with drug (medication) treatment. The analysis was stratified by T2D status. The Form1 and Form2 are described in the text, they are not approved by FDA. Met: Merformin, Sibut: Sibutramine, Orlit: Orlistat, Glim: Glimepiride, Phent: Phentermine, Top: Topiramate. REML: Restricted maximum likelihood.

Supplemental Figure 1. Meta regression of medication mean difference effects on HDL-C (upper panel) and triglycerides (lower panel) concentrations, adjusted by mean age, BMI, duration of treatment (months), geographical latitude and use of placebo or active comparator. The grey zone represents the 95%CI of the regression. Liraglutide was used in the highest obesity and geographical sites at North. The Form1 and Form2 are described in the text, they are not approved by FDA. Met: Merformin, Sibut: Sibutramine, Orlit: Orlistat, Glim: Glimepiride, Phent: Phentermine, Top: Topiramate.

Supplemental Figure 2. Meta regression of medication mean difference effects on diastolic blood pressure adjusted by mean age, BMI, duration of treatment (months), geographical latitude and use of placebo or active comparator. The upper panel shows the effect of BMI and the lower panel the geographical location. The grey zone represents the 95%CI of the regression. Liraglutide was used in the highest obesity and geographical sites at North. The Form1 and Form2 are described in the text, they are not approved by FDA. Met: Merformin, Sibut: Sibutramine, Orlit: Orlistat, Glim: Glimepiride, Phent: Phentermine, Top: Topiramate.

Supplemental figure 3. Network meta-analysis of the studies examining the efficacy of drug treatments in patients with obesity in (A) BMI in non-diabetic patients compared to placebo, (B) BMI in patients with diabetes compared to metformin. The colors of edges and nodes refer to the risk of bias: low (green), moderate (yellow), and high (red). The dosage of DHA and EPA are in mg per day. Met: Metformin. Diac+Met: Diacerin + Metformin. The Form1 and Form2 are described in the text, they are not approved by FDA. Plc: Placebo.




Figure 1

849 850





Figure 2.

852 853




Random-effects REML model

Figure 3.

855 856






Random-effects REML model

Figure 4.


858 859



Random-effects REML model

Figure 5.

861 862



-2

-1


0

Random-effects REML model

Figure 6.

864 865






Random-effects REML model

Figure 7.

867 868






Random-effects REML model

Figure 8.

870

871




Random-effects REML model

Figure 9.

873 874





Random-effects REML model

Figure 10.

876 877

879

Table 1. Characteristics of the analyzed interventions (n=58). Duration of study: ( $\alpha$ ) < 3 months, ( $\alpha$ )  $\alpha$  = 12 months. The requestion of study: ( $\alpha$ ) < 3 months.

Category	N	%	References
Study Design			
A. Drugs	28	48.3	
A1. Non- diabetic patients	17 (* § «)	29.3	(24-38)
A2. Diabetic patients	11 (*)	19.0	(39-45)
B. Nutrition and exercise	28	48.3	
B1. Food and supplements	11 (* «)	19.0	(31, 46-54)
B2. Diet	6 (* «)	10.3	(50, 55-58)
B3. Behavioral	1 (*)	1.7	(59)
B4. Exercise	1 (*)	1.7	(60)
B5. Multi-component	7 (* «)	12.1	(50, 51, 60-62)
B6. Alternative	2 («)	3.4	(63-65)
C. Surgery	2	3.4	
C1. Cx	1 (§)	1.7	(67)
C2. Cx-diet	1 (*)	1.7	(68)
Gender †			
Male	5	11.1	(25, 28, 54, 60, 64)
Female	9	20	(29, 30, 50, 51, 57, 59, 61, 63, 68)
Both	31	68.9	(24, 26, 27, 31-49, 52-56, 58, 59, 62, 65, 67, 69)
Age †			02, 00, 07, 00)
Youth (18-35)	11	24.4	(24, 46, 47, 49-51, 54, 58, 68)
Young adults (36-45)	21	46.7	(25, 27-29, 33-37, 39, 42, 43, 48,
Older adults (46 or more)	13	28.9	52, 53, 56, 60-63, 69) (24, 26, 40-42, 44, 45, 57, 59, 65,
Older addits (40 OF HIOTE)	13	20.9	(24, 26, 40-42, 44, 45, 57, 59, 65, 67)
City †			
México City	17	37.8	(29, 32, 35-38, 40, 41, 43, 45, 54, 59, 62, 63, 65, 67)
Guadalajara	13	28.9	(24, 25, 31, 33, 39, 42, 44, 47-49, 52, 56, 68)
Cd. Madero	3	6.7	(26, 27, 58)
Cuernavaca	2	4.4	(55, 69)
Durango	2	4.4	(57, 61)

Querétaro	2	4.4	(50, 51)
Tijuana	2	4.4	(46, 64)
León	1	2.2	(60)
Monterrey	1	2.2	(34)
San Luis Potosí	1	2.2	(30)
Villahermosa	1	2.2	(53)

Table 2. Descriptive characteristics and assessment of Nutrition/behavior interventions.

Author State Year	Participants	Sample size	Intervention implemented/Control	Number of Participants (basal, final)	Treatment duration	Aims/Outcomes	Significance difference between groups
Moran <sup>62</sup> Mexico City 1997	Male and Female Intervention: 39 ± 15; Control: 38 ± 10 years old.  BMI ≥30 Kg/m²	36	Intervention: diet + 750 mg ursodeoxycholic acid (AUD) + fiber placebo  Control: diet + 15g Plantago psyllium (pp) + AUD placebo	Intervention: 18, 18 Control: 18, 18	2 months	Primary: prevention of gallstone disease (GD) in obese subjects undergoing a weight-reduction diet. Cholesterol crystals in duodenal bilis were used as surrogate of GD risk.	Yes: Treated individuals had less presence of cholesterol crystals.
Rodriguez- Hernandez <sup>61</sup> Durango 2009	Female  45.4 ± 10.4 years old  BMI ≥30 Kg/m²	105	Intervention: Cognitive behavioral treatment + Low carb diet or low- fat diet  Control: Non cognitive behavioral treatment	Intervention: 55, 52 Control: 50, 50	6 months	Primary: weight loss.  Secondary: Depression and anxiety, fasting glucose and triglycerides.	Yes: CBT-LF had significant differences were observed in waist circumference, weight, and BMI in the and significantly decreased body fat, weight, BMI and triglycerides compared with C-LF group.
Ble-Castillo <sup>53</sup> Tabasco 2010	Male and Female 51.7 ± 5.6 years old BMI ≥30 Kg/m² T2DM	30	Intervention: Native Banana Starch Control: Soy Milk	Intervention: 15, 14  Control: 15, 14	2 months	Primary: Body weight and insulin sensibility.  Secondary: Cholesterol; HDL; Triglycerides; Diastolic blood pressure; Systolic blood pressure; Waist to hip ratio; Calcium; Phosphates.	Yes: Body weight, BMI, waist to hip ratio and triglycerides significantly reduced.  No: No significant changes in glucose and HbA1c. A decrease in serum triglycerides in control group. No changes were observed on calcium, phosphate and hematological markers such as white blood cells, platelets and other indexes
Rodriguez- Hernandez <sup>57</sup> Durango 2011	Female Intervention: 46.3 ± 9.1; Control: 45 ± 9.1 years old.  BMI ≥30 Kg/m²	59	Intervention: low carbs diet (LCD)  Control: low fat diet (LFD)	Intervention: 31, 28 Control: 28, 26	6 months	Primary: To evaluate decrease aminotransferase levels.	No: No significant differences in anthropometric and biochemical characteristics between groups

	NAFLD						
Rosado <sup>51</sup> Queretaro 2011	Female  34 ± 6 years old  BMI ≥30 Kg/m <sup>2</sup>	139	Intervention 1: Low fat milk Intervention 2: Low fat milk with added micronutrients Control: No milk intake	Intervention 1: 46, 33 Intervention 2: 46, 37 Control: 47, 31	4 months	Primary: To evaluate anthropometrics, body composition, blood glucose levels, lipids profile, C-reactive protein, and blood pressure.	Yes: LFM+M group had significant weight loss than control and LFM+M group. Body fat among LFM+M group members was significantly higher than LFM and control group.  No: No differences between groups in glucose level, blood lipid profile, blood pressure, or C-reactive protein level.
Madero <sup>58</sup> Mexico City  2011	Male and female  Intervention 1: 37.56 ± 1.14; Intervention 2: 40.15 ± 1.01.  BMI > 25 Kg/m <sup>2</sup>	131	Intervention 1: Low fructose diet Intervention 2: Moderate natural fructose diet	Intervention 1: 65, 65 Intervention 2: 66, 66	1.5 months	Primary: weight loss.  Secondary: Quality of life scores, blood pressure, lipid profile, serum glucose, insulin resistance, uric acid, and soluble intercellular adhesion molecule-1	Yes: Significant weight loss compared with baseline in both treatments, but higher in the MNF group. Significant improvement in secondary outcomes in both treatments
Tovar <sup>50</sup> Queretaro 2012	Female  Intervention 1:  34.62 ± 7.4; Intervention 2:  33.17 ± 7.63; Intervention 3:  32.58 ± 8.13; Control: 33.39 ±  8.72 years old.  BMI ≥ 25 Kg/m²	144	Intervention 1: Partial meal replacement (PMR) + Inulin (INU) Intervention 2: PMR Intervention 3: INU Control: No additional treatment	Intervention 1: 36, 23 Intervention 2: 36, 28 Intervention 3: 36, 30 Control: 36, 29	3 months	Primary: weight reduction, blood lipids and micronutrients.	Yes: all groups significantly reduced BMI, weight, waist and hip circumference. Subjects in PMR+INU, PMR and INU significantly decreased triglycerides. Fiber intake increased in PMR+INU and INU groups. In PMR and PMR+INU groups some minerals and vitamins intakes increased compared with INU and control groups.
Martinez- Abundis <sup>49</sup> Jalisco  2013	Male and female  Intervention: 35.4 ± 4.3; Control: 35.4 ± 3.8 years old.	14	Intervention: Avocado Soybean Unsaponifiable (ASU)  Control: Placebo	Intervention: 7, 7 Control: 7, 7	3 months	Primary: Glucose, triglycerides, HDL□C, leptin, C□reactive protein (CRP), TNFα, adiponectin, erythrocytes, fatty acids and metabolic syndrome.	No: No differences between groups before and after the two treatments in hs-CRP, IL-6, insulin secretion, and insulin sensitivity

	BMI 30-39.9 Kg/m <sup>2</sup>						
Perichart- Perera <sup>59</sup> Mexico City  2014	Postmenopausal Female Intervention: 54.81 ± 6.38; Control: 52.65 ± 6.35 years old. BMI ≥ 25 Kg/m² MetS	118	Intervention: Behavioral therapy  Control: Structured hypocaloric diet	Intervention: 55, 55 Control: 63, 63	6 months	Primary: metabolic syndrome.  Secondary: weight, waist circumference, systolic and diastolic blood pressure, cholesterol, triglycerides, body fat mass	Yes: Higher reduction in MetS prevalence in BT group. Significant decrease in weight and waist circumference in both groups. Control group significantly decreased systolic and diastolic blood pressure, and fat mass measurements. Control group decrease total cholesterol and triglyceride
Hernandez- Cordero <sup>69</sup> Morelos 2014	Women  Intervention: 33.5 ± 6.7; Control: 33.3 ± 6.7 years old.  BMI ≥ 25 Kg/m²  MetS	240	Intervention: Water and Education provision (WEP)  Control: Education Provision (EP)	Intervention: 120, 102 Control: 120, 87	9 months	Primary: to determine if replacing SSBs with water affects plasma triglycerides (TGs), weight, and other cardiometabolic factors.	No: No effect on plasma TGs, weight, and other cardiometabolic risks in the ITT analysis.
Macias- Cervantes <sup>60</sup> Guanajuato 2015	Male  Intervention 1: 40 ± 4.8; Intervention 2: 43.5 ± 7.1; Intervention 3: 44.3 ± 5.3 years old.  BMI ≥ 25 Kg/m²	43	Intervention 1: Low AGE diet  Intervention 2: Exercise with regular food intake  Intervention 3: Exercise with low AGE diet	Intervention 1: 14 Intervention 2: 14 Intervention 3: 15	3 months	Primary: Identify the effect of a low advanced glycation end product (AGEs) diet, exercise, and a combination of both on circulating AGE levels as well as on plasma lipids and anthropometric parameters. Secondary: blood pressure, beats per minute, Diet-Cal, fasting blood glucose, HDL-C, heart rate, LDL-Cholesterol, VO2 (oxygen consumption)	Yes: The group with low AGE diet showed differences in weight, BMI, waist circumference, serum AGEs. Group with normal diet + exercise: weight, BMI, waist circumference, heart rate max and VO2max. Group with low AGE diet +exercise: weight, BMI, waist, triglycerides, HDL, LDL, serum AGEs, and VO2max
Romero-Prado <sup>56</sup> Jalisco	Male and female 42.2 ± 7.5 years	110	Intervention: Flavonoids Diet + Anti-hypertensive therapy	Intervention; 40, 40	6 months	<b>Primary:</b> blood pressure, lipid profile, obesity and inflammation	Yes: SBP, DBP, cholesterol and triglycerides, BMI,

2015	old  BMI 25-34.9  Kg/m²  Hypertension according to WHO criteria		(Captopril/Telmisartan)  Control: Anti-hypertensive therapy (captopril/Telmisartan)	<b>Control:</b> 70, 39			waist circumference and CRP showed differences at 3 and 6 months in the intervention group. HDL only when comparing baseline & 6 months.  No: Leptin levels
Campos- Nonato <sup>55</sup> Morelos 2017	Male and female  47.4 ± 11.5 years old  BMI 25-45 Kg/m <sup>2</sup> MetS	118	Intervention: High-Protein Diet  Control: Standard-Protein Diet	Intervention: 59,59 Control: 59, 46	6 months	Primary: Evaluate the effect of increased protein intake on weight loss in adults with MetS.  Secondary: (all measured in baseline, 3 and 6 months): fasting blood glucose, fasting insulin, hemoglobin A1c, total cholesterol, high-density lipoprotein (HDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol, triglycerides, C-reactive protein, creatinine, blood urea nitrogen, alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase.	Yes: Decreased weight, % of abdominal fat. Differences observed in both groups: waist circumference, Systolic blood pressure, fasting blood glucose, insulin, HOMA index, triglycerides, total cholesterol, VLDL cholesterol. The group SDP, presented a difference in HDL and direct bilirubin.
Leyva-Soto <sup>46</sup> Baja California 2018	Male and female  Intervention: 23.8 ± 3.4; Control: 23.6 ± 3.5 years old.  BMI > 29 Kg/m <sup>2</sup> MetS	92	Intervention: Dark chocolate  Control: Milk Chocolate	Intervention: 42, 42 Control: 50, 42	6 months	Primary: Evaluate the genoprotective effect of consuming a flavonoidsrich chocolate.  Secondary: Biochemical parameters related to cardiovascular risk and metabolic syndrome: changes in BMI, waist circumference, Fasting plasma glucose, HOMA, HbA1c, Systolic blood pressure, Diastolic blood pressure, Cholesterol total, triglyceride, Nuclear Abnormalities in Buccal	Yes: abnormalities of the nuclei in the buccal epithelial cells decreases significantly (less than 2%) after 6 months of daily consumption of 2g of dark chocolate. Decreased BMI, waist circumference, Total cholesterol, LDL Cholesterol, triglycerides, HOMA-IR, fasting plasma glucose, systolic and diastolic blood pressure in the group commercial dark

						Epithelial Cells.	chocolate.
Padilla- Camberos <sup>47</sup> Jalisco 2018	Male and female 20-55 years old BMI > 30 Kg/m <sup>2</sup>	28	Intervention: Agave fructans  Control: Maltodextrin	Intervention: 14, 14 Control: 14, 14	3 months	Primary: Effects of agave fructans on weight control, lipid profile, and physical tolerability. Weight, hip, waist, hip waist index, total body fat (%), glucose, serum insulin, total cholesterol, (HDL) and (LDL) cholesterol, triglycerides.  Secondary: Safety assessments were performed Weight, hip, waist, hip waist index, total	Yes: BMI and triglycerides of the Agave fructans treated
						body fat (%), glucose, serum insulin, total cholesterol, HDL and LDL	
						cholesterol, triglycerides.	

Table 3. Descriptive characteristics and assessment of Medications.

Author	Intervention Participants	Commis	Intervention	Number of	Treatment	Aims/Outcomes	Significance difference
State Year	Participants	Sample size	implemented/Control	Participants (basal, final)	duration	Aims/Outcomes	between groups
anghänel <sup>41</sup>	Male and Female	60	Intervention: Metformin	Intervention: 30, 28	3 months	<b>Primary:</b> glucose and lipid metabolism.	Yes: Metformin had beneficial effects on insulin resistance
Mexico City 1996	Intervention: 52.1 ± 8.8; Control: 51.2 ± 8.5 years old.		Control: Insulin	Control: 30, 30		Secondary: Glycosylated hemoglobin, BMI, blood	hypertension, overweight, an hyperlipidemia.
	BMI > 27 Kg/m <sup>2</sup>					pressure.	
40	NIDDM						
Fanghänel <sup>40</sup>	Male and Female	120	Intervention: Metformin, Insulin	Intervention: 60, 60	3 months	Primary: levels fibrinogen.	Yes: The insulin grou showed decrease on glucose
Mexico City 1998	Intervention: 49.3 ± 9.6; Control: 47.1 ± 7.3 years old.		Control: Diet	<b>Control:</b> 60, 60			fibrinogen levels and BMI.
	BMI >27						
	T2DM						
Cuellar <sup>36</sup>	Male and female	69	Intervention: Sibutramine	Intervention: 35, 22	6 months	<b>Primary:</b> Safety and efficacy of sibutramine.	Yes: Sibutramine induce significant loss of body weigh
Mexico City	Intervention: 38.44 ± 10.09; Control:		Control: Placebo	Control: 34, 9		Secondary: waist	and waist circumference. N significant adverse events
2000	38.62 ± 9.12 years old.					circumference and waist/hip ratio. Appetite, satiety, and diet adherence were also	significant adverse events NOTE: Sibutramine wa withdrawn in 2010.
- 37	BMI >30 Kg/m <sup>2</sup>					evaluated.	
Fanghänel <sup>37</sup>	Male and female	109	Intervention: Sibutramine	Intervention: 55, 40	6 months	<b>Primary:</b> Safety and efficacy of sibutramine 10	Yes: Sibutramine induce significant loss of BMI an waist, but does no
Mexico City	Intervention: 38.09 ± 10.11; Control:		Control: Placebo	Control: 54, 44		mg.	oignificantly offor
2000	39.48 ± 10.26 years old.					Secondary: Waist circumference and waist/hip	cardiovascular function. N significant adverse events
	BMI >30 Kg/m <sup>2</sup>					ratio, blood pressure and heart rate and clinical laboratory.	significant adverse events NOTE: Sibutramine wa withdrawn in 2010.  Yes: Patients had weigl gain, but they did not reac
anghänel <sup>38</sup>	Male and female	82	Intervention: Sibutramine	Intervention: 40, 40	6 months	Primary: Endpoints for the	Yes: Patients had weigh
	Intervention: 40.1 ±		Control: Placebo	Control: 44, 42		trial were the body weight and BMI.	gain, but they did not read the baseline body weight. Note: Sibutomine

	BMI >30 Kg/m <sup>2</sup>					ratio, appetite, satiety and diet adherence and adverse events.	
Zaragoza <sup>35</sup> Mexico City 2001	Male and Female  Intervention 1: 36.84 ± 9.16; Intervention 2: 36.79 ± 10.61; Control: 36.77 ± 9.18 years old.  BMI > 30 Kg/m <sup>2</sup>	210	Intervention 1: D- norpseudoephedrine 50 mg, triiodothyronine 75 ug, diazepam 5 mg, atropine 0.36 mg, aloin 16.2 mg.  Intervention 2: D- norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 16.2 mg.  Control: Placebo	Intervention 1: 69, 59 Intervention 2: 70, 51 Control: 69, 26	6 months	Primary: Update data on the efficacy and safety of two formulations of d-norpseudoephedrine in prolonged-release capsules, which have been used successfully in the treatment of obesity since 1956 and 1995.	Yes: The efficacy and safety of formulations 1 and 2 in the pharmacological treatment of obesity are confirmed, these d-norpseudoephedrine formulations maintain the weight reduction achieved for periods of at least six months, without causing addiction or inducing tolerance with loss of effectiveness after a shorted period. NOTE: Not approved by FDA.
Halpern <sup>45</sup> Multinational 2003	Male and Female Intervention: 50.88 ± 1.37; Control: 50.79 ± 1.48 years old.  BMI> 27 Kg/m²  NIDDM	343	Intervention: Orlistat Control: Placebo	Intervention:169, 139 Control: 174, 141	6 months	Primary: To determine if obese non-insulindependent diabetic patients lose more weight when treated for 24 weeks with orlistat, in conjunction with a hypocaloric diet plus behavioral counselling, than when treated by placebo plus similar instructions.  Secondary: To evaluate the effects on glucose profile and to determine the tolerability and safety of orlistat.	Yes: Orlistat group lost greater body weight vs. in the placebo group, Orlistat treatment plus diet compared to placebo plus diet was associated with significant improvement in glycaemic control, as reflected in decreases in HbA1c, fasting plasma glucose anappostprandial glucose and greater improvements than placebo in lipid profile, with reductions in total cholester and LDL-c.

Gonzalez-Ortiz <sup>44</sup>	Male and Female	104	Intervention 1: Glimepiride	Intervention 1: 37,	3 months	Primary: To evaluate the	Yes: The percentage of patients that improved A1C
Jalisco	Intervention 1: 53 ±		Intervention 2: Metformin	37		efficacy and safety of glimepiride plus metformin	patients that improved A1C
Jansco	8: Intervention 2:		intervention 2. Wettomin	Intervention 2: 33,		in a single presentation, as	glimepiride. metformin and
2004	53 ± 7; Intervention		Intervention 3: Glimepiride +	33		combined therapy, in	their combination groups.
	3: 53 ± 7 years old.		Metformin	Intervention 3: 34,		patients with T2DM with secondary failure to	
	BMI >27 Kg/m <sup>2</sup>			34		glibenclamide.	
	T2DM with A1c >						restients that improved A1C levels to less than 7% were in glimepiride, metformin and their combination groups.  Yes: Zinc increased the leptoconcentrations in obese.  No: No significant changes insulin sensitivity androgens after the intervention.
	078						
							<u>~</u>
Gómez-García <sup>54</sup>	Mala	14	Intervention: Zinc sulfate	Intervention: 7-7	20 dove	Drimony Inquity consists its	Vec. 7ine increased the lent
Gomez-Garcia	Male	14	intervention: Zinc suifate	Intervention: 7, 7	30 days	<b>Primary:</b> Insulin sensitivity, leptin and androgens.	concentrations in obese.
Jalisco	Intervention: 21.8 ±		Control: placebo	Control: 7, 7			/aila
2006	2.8; Control: 25.1 ± 4.5 years old.					<b>Secondary:</b> Glucose, total cholesterol, HDL-c, LDL-c,	No: No significant changes 65 a
2000						VLDL-c, triglycerides,	androgens after the
	BMI ≥27 Kg/m <sup>2</sup>					creatinine, uric acid, TT, TL, SHBG.	androgens after the city intervention.
Toplak <sup>34</sup>	Male and female	430	Intervention 1: Orlistat + Diet -500 kcal	Intervention 1: 215, 141	12 months	<b>Primary:</b> To determine the effect of two different levels	No: Treatment with orlist
Multinational	Intervention 1: 41.3					of energy deficit on weight	clinically beneficial weight
2005	± 11.0; Intervention 2: 41.1 ± 12.1 years old.		Intervention 2: Orlistat + Diet -1000kcal	Intervention 2: 215, 154		loss in obese patients treated with orlistat.	loss, irrespective of the prescribed dietary energy restriction.
	BMI 30-43 Kg/m <sup>2</sup>						4.0 Ir
22							nten
Gonzalez-Ortiz <sup>33</sup>	Male and Female	12	Intervention: Ezetimibe	Intervention: 6, 6	3 months	<b>Primary</b> : To evaluate the effect of ezetimibe on	Yes: Ezetimibe administered
Jalisco	Intervention: 37.3 ±		Control: Placebo	Control: 6, 6		insulin sensitivity and lipid	and low-density lipoproteid
2006	6.7; Control: 38.5 ± 5.8 years old.					profile in obese and dyslipidemic patients.	cholesterol concentrations.
2000	5.6 years old.					dyshpidernic patients.	No: Insulin sensitivity.
	BMI: 25-35 Kg/m <sup>2</sup>						no: Insulin sensitivity.  Yes: Metformin has effect on endothelial function and nitroxidation.
	Dyslipidaemia						
Meaney <sup>32</sup>	Male and female	60	Intervention: Metformin	Intervention: 30, 22	12 months	Primary: To evaluate the	Yes: Metformin has effect on
Mexico City	Intervention: 49 ±		Control: Diet	Control: 28, 17		effect of metformin on metabolic syndrome in IGT	endothelial function and of nitroxidation.
,	10; Control: 49 ± 8		2	23 2 23, 17		patients.	nitroxidation.  No: No-effect on BMI.
2008	years old.						
	MetS						7
Hernandez- Gonzalez <sup>52</sup>	Male and Female	12	Intervention: Chitosan	Intervention: 6, 6	3 months	Primary: Insulin sensitivity.	Yes: Increased insuling sensitivity and decrease

Ioliana	Intervention: 41.6 ±		Control: Placebo	Control: 6, 6		Secondary: Glucose, HDL-	weight, BMI, waist
Jalisco 2010	6.3; Control: 42.6 ± 5.6 years old.					c, LDL-c and triglycerides.	circumference and TG.
	BMI: 30-40 Kg/m <sup>2</sup>						
	Without DM						
Martinez- Abundis <sup>31</sup>	Male and female	18	Intervention 1: Placebo and metformin	Intervention 1: 9, 9	3 months	<b>Primary:</b> To compare the effect of metformin and	Yes: The three pharmacological interventions
Jalisco	Intervention 1: 29.5 ± 6.3; Intervention		Intervention 2: Sibutramine	Intervention 2: 9, 9		sibutramine as monotherapy or as	1
2010	2: 26.1 ± 4.0; Intervention 3: 29.6		and placebo	Intervention 3: 9, 9		combined therapy on insulin sensitivity and adiposity in	reduced BMI at different magnitudes. Metforming improved insulin sensitivity. Sibutramine decreased adiposity. Metformin as monotherapy or combined with sibutramine had appreciately effect on line.
	± 5.5 years old.		Intervention 3: Sibutramine and metformin			obese patients.	adiposity. Metformin as monotherapy or combine
	BMI 30-40 Kg/m <sup>2</sup>					Secondary: To evaluated Blood pressure, ITT, glucose, total cholesterol,	profile
Ramos-Zavala <sup>39</sup>	Male and female	40	Intervention: Diacerein	Intervention: 20, 20	2 months	Primary: Insulin secretion	Yes: Significant increases
Jalisco	Intervention: 47.5 ± 5.3; Control: 47.7 ±		Control: Placebo	<b>Control:</b> 20, 20		and metabolic control (included interleukin IL-Iß, TNF-a, IL-6).	first, late and total insuling fasting glucose and A1 levels, TNF-a, IL-6.
2011	5.2 years old.					2, 12 3/1	No: Without significant
	BMI > 25						differences in total
	T2DM with <6 months since diagnosis						triglycerides, VLDL-c and metabolized glucose
González- Acevedo <sup>30</sup>	Women	60	Intervention 1: 1 g of Omega-3	Intervention 1: 20, 20	3 months	Primary: To assess the effect of omega-3	Yes: Supplementation significantly reduced weight
San Luis Potosi	Intervention 1: 31.65 ± 7.41;		Intervention 2: 2 g of	Intervention 2: 20,		supplementation on BMI, WHI and body composition	yes: Supplementation significantly reduced weight BMI, and total fat mass compared to the control group, a dose-response effect, but these effect depended on the time and amount of Omega 3 supplemented, when the degree of compliance of exercise adherence to the
2013	Intervention 2: 28.45 ± 8.15;		Omega-3	20		of obese women using bioelectrical impedance.	group, a dose-response effect, but these effects
	Control: 30.70 ± 6.87 years old		Control: Placebo+ Vitamin E (200 IU)	Control: 20, 20			amount of Omega 3
	BMI > 30 Kg/m <sup>2</sup>						degree of compliance of
							diet and age were controlled.
							degree of compliance of exercise, adherence to the diet and age were controlled.

Sánchez-Muñoz <sup>29</sup>	Women	19	Intervention: Metformin	Intervention: 9, 8	3 months	Primary: To establish the	Yes: It was significative changes in Arterial tension,
Mexico City	25-60 years old		Control: Exercise	<b>Control</b> : 10, 8		effectiveness of aerobic exercise and its influence in	HOMA-IR and insulin.
2013	BMI >24,9 Kg/m <sup>2</sup>					reducing cardiovascular risk in overweight or obese women with NAFLD.	HOMA-IR and insulin.  No: Was not significative differences in fatty liver.
Hernandez- Corona <sup>48</sup> Jalisco	Male and female Intervention: 45.4 ± 7.3; Control: 42.4 ± 3.7 years old.	25	Intervention: F Fucoidan  Control: Placebo	Intervention: 13, 11 Control: 12, 8	3 months	Primary: Evaluate changes in insulin secretion and insulin resistance.  Secondary: Weight, blood	Yes: Significant decrease in DBP and LDL-c, Increase in insulin levels, HOMA B-cells and HOMA IR.  No: BMI.
2014	BMI: 25-34.9 Kg/m <sup>2</sup>					pressure, glucose, total cholesterol, HDL-c, TG and IR.	No: BMI.
Hernandez- Bastida <sup>43</sup> Mexico City 2015	Male and female  18-65 years old  BMI 25-40 Kg/m <sup>2</sup> T2DM	120	Intervention: Topiromate + Phentarmine  Control: Placebo + Phentarmine	Intervention: 60, 54 Control: 60, 53	3 months	Primary: Efficacy and safety of the combination of phentermine plus topiramate.  Secondary: To evaluate the impact of the combination over risk and safety factors.	Yes: The combination showed reduction in weight BMI, waist, circumference lipids and glucose. The most frequent adverse events were paresthesia and dry mouth
O´Neil <sup>27</sup> Multinational 2016	Male and female  Hispanic Age: Intervention: 41.4 ± 11.4; Control: 41.0 ± 11.7 years old.  BMI ≥27 Kg/m² with at least 1 comorbid condition or BMI ≥30 Kg/m²	5131 Hispanic: 534	Intervention: Liraglutide  Control: Placebo	Intervention: 3289, 3289  Control: 1842, 1842  Hispanic participants:  Intervention: 341, 341  Control: 193, 193  (their data were combined with other ethnic groups)	3 studies of 56 weeks 1 study of 32 weeks	Primary: Efficacy and safety of liraglutide.  Secondary: Weight and risk factors.	these effects decreased in frequency and intensity during the study.  Yes: Efficacy and safety were largely similar between Hispanic and non-Hispanic.

							<b>₹</b> ₫
Sánchez-	Healthy	100	Intervention: Hormone	Intervention: 50, 46	6 months	Primary: Oxidative stress.	Yes: After 6 months, Mets and decreased in the hormone treated group (48%), striglycerides and HDL-c; the controls did not show differences. SS in MSW-HT decreased (3.8 ± 0.3 to 1.7 ± 0.3, p < 0.05) and Oxidative stress was also reduced (44%), this effect was evident since 3 mo. HW-HT with high OS also decreased (40%).  In placebo groups there was no change.  Yes: Significant decrease in each of the control
Rodriguez <sup>28</sup>	postmenopausal		therapy				decreased in the hormone 🗜 🕏
•	women or with			Control: 50, 45			treated group (48%), ₹ ⊆
Mexico City	MetS.		Control: Placebo				triglycerides and HDL-c; the
,							controls did not show
2016	Healthy women:						differences SS in MSW-HT ?
	Intervention: 52 ±						decreased (3.8 + 0.3 to 1.7 + $\frac{3}{8}$ )
	0.6; Control: 53 ±						0.3 n < 0.05) and Oxidative
	0.7 years old.						stress was also reduced
	o.r yours old.						(44%) this effect was evident
	MetS women:						since 3 mg HW-HT with high
	Intervention: 52 ±						OS also decreased (40%)
	0.7: Control: 53 ±						OS also decreased (40 %).
	0.7, Control. 55 ± 0.9 years old.						In placebo gravno thora we
	0.9 years old.						in placebo groups there was
		4.0	1 1 1 1		0 11	<b>5</b>	no change.
	Male and Female	12	Intervention: Metformin +	Intervention: 6, 6	3 months	Primary: Glycemic control.	Yes: Significant decrease in 6
Villar <sup>42</sup>			Diacerein				fasting glucose, postprandial
	Intervention: 41.3 ±			Control: 6, 6			glucose and A1C.
Jalisco	9.7; Control: 54 ±		Control: Metformin				ble 3
	3.5 years old.						u <del>(†</del>
2017							nd nd
	BMI: 25-34.9 Kg/m <sup>2</sup>						9 ∰ 1
							a de
	T2DM and						87
	inadequate						<u>``</u> ` ♣ 5
	glycemic control						<b>₹</b> ₽.
							NO N
Gonzalez-	Male and female	16	Intervention: Linagliptin	Intervention: 8, 8	3 months	Primary: To assess the	Yes: Group with linagliption of
Heredia <sup>24</sup>						effect of linagliptin versus	had decrease in glucose ∰ Š
	Intervention: 49.3 ±		Control: Metformin	Control: 8, 8		metformin on glycemic	levels at 120 min of OGTT.
Jalisco	5.7; Control: 51.9 ±					variability in patients with	<del>-</del> + 5
	6.4 years old.					IGT.	No: No significant differences
2017	,						in the AUC. MAGE. SD 矿为
	BMI 25-34.9 Kg/m <sup>2</sup>						glucose. CV of glucose. and ≱.₫
							MBG between groups.
	Impaired Glucose						= 6
	Tolerance						C en C
Gonzalez-Ortiz <sup>25</sup>	Male	18	Intervention: Taladafil	Intervention: 9, 9	28 days	Primary: Blood pressure,	No. After the administration of $\Phi$
CONZUICZ CHUZ	IVIGIO	10	mior ontion raiddan	into vontion o, o	20 day5	cholesterol, triglycerides,	tadalafil there were no
Jalisco	Intervention: 40.2 ±		Control: Placebo	Control: 9. 9		HDL-c, LDL-c, glucose.	significant differences in total #: 0
Jansto	7.9; Control: 38.4 ±		33.11.01.1 100000	<b>Jona 31.</b> 3, 3		TIDE 0, EDE 0, glucose.	inculin secretion first phase of
2017	6.4 years old.						inculin secretion and inculin
2017	U.4 years old.						consitivity No significant
	BMI 30-39.9 Kg/m <sup>2</sup>						differences were shown in the
	DIVII 30-39.9 Ng/III						other measurements
Le Roux <sup>26</sup>	Male and female	2254	Intervention, Linearitide	Intervention: 1505	40 months (2.2	Drimorus Evoluato 45 a	Voc. Time to areat of #1.00
Le Roux	iviale and temale	2254	Intervention: Liraglutide	Intervention: 1505, 783	40 months (3.3	<b>Primary</b> : Evaluate the proportion of individuals	tes: time to onset of
Multipotional	Intervention, 47.5	Uiononio-	Cantual: Discales	783	years)	proportion of individuals	diabetes over the 40 months 3 c
Multinational	Intervention: 47.5 ±	Hispanic:	Control: Placebo		years)	with prediabetes who were	among all randomized
	Intervention: 47.5 ± 11.7; Control: 47.3 ± 11.8 years old.	Hispanic:	Control: Placebo	Control: 749, 327	years)	with prediabetes who were diagnosed with type 2 diabetes.	Yes: Group with linaglipting of the line o

BMI ≥27 Kg/m²		Hispanic participants Intervention: 143
Dyslipidemia, or hypertension, or both		Control: 70
5001		(their data were gathered with other individuals)

Secondary: GLP-1 receptor agonist, waist circumference (cm), glycated hemoglobin (%), 2-h plasma glucose during OGTT (mmol/L), Free fatty acids (mmol/L), Blood pressure (mm Hg).

with placebo.

Greater weight loss than be placebo at month 40: BMI, waist circumference, glycated hemoglobin, fasting glucose, continuo fasting insulin, fasting C-peptide, glucose levels in the placebo de pressure, and heart blood pressure, and heart blood pressure, and heart blood pressure.

893

901

NIDDM: Non-insulin dependent diabetes mellitus; BMI: Body mass index; T2DM: Type 2 diabetes mellitus; FDA: Food and Drug Administration; A1c: Glycated hemoglobin; HDL: High density lipoprotein; LDL: Low density lipoproteins; VLDL: Very low density lipoprotein; TT: Total testosterone, TL: Free testosterone, SHBG: Sex Hormone Binding Globulin; MetS: Metabolic syndrome; IGT: Impaired glucose tolerance; TG: Triglycerides; ITT: Insulin tolerance test; IL-Iß: Interleukin 1 beta; IL-6: Interleukin-6; TNF-a: Tumour Necrosis Factor alpha; WHI: Waist Hip Index: NAFLD: Non-alcoholic fatty liver disease: IR: Insulin resistance: HOMA-IR: Homeostasis model assessment of IR: HOMA B-cells: Homeostatic Model Assessment-beta-cell function; SS: Stress score; MSW-HT: MetS women were assigned to HT (hormone therapy); HW-HT: Healthy-hormone therapy; OS: Oxidative stress; OGTT: Oral glucose tolerance test; AUC: Area under the curve; MAGE: Mean amplitude of glycemic excursion, SD: Standard deviation; CV: Coefficient of variation; MBG: Mean blood glucose; GLP-1: Glucagon-like peptide-1.

Table 4. Descriptive characteristics and assessment of Medications.

gical and Alterr Author State Year	native Intervention Participants	Sample size	Intervention implemented/Control	Number of Participants (basal, final)	Treatment duration	Aims/Outcomes	Significance difference between groups
Robles- Cervantes <sup>68</sup> Jalisco 2007	Female  Intervention: 34.0 ± 3.7; Control: 34.6 ± 3.6 years old.  BMI: 30-33 Kg/m <sup>2</sup>	12	Intervention: Liposuction and diet  Control: Diet	Intervention: 6, 6 Control: 6, 6	6 months	Primary: Visceral fat, Insulin sensitivity, leptin and tumor necrosis factor alfa.  Secondary: Glucose, Creatinine, Uric acid, Total cholesterol, HDL cholesterol, Triglycerides.	Yes: Leptin correlated with the subcutaneous fat.  No: no significant difference in insulin sensitivity and did not correlate with subcutaneous fat, leptin, or TNF-alpha.
Arceo-Olaiz <sup>67</sup> Mexico City  2008	Male and Female  Intervention: 36.5 ± 9.7; Control: 37.8 ± 9.6 years old.  BMI: 40-55 kg/m2	60	Intervention: Laparoscopic roux- en - y gastric bypass (LRYGB)  Control: banded LRYGB (BLRYGB)	Intervention: 30, 30 Control: 30, 30	24 months	Primary: Weight loss	No: The studied groups di not have significar differences in weight loss a 6, 12, and 24 months. The frequency of complication was similar in both groups.
García-Vivas <sup>63</sup> Durango 2014	Women  18-45 years old  BMI ≥25 Kg/m²  without known MetS	138	Intervention: Accupunture Control: Sham Accupunture	138, 99	2 months	Primary: anthropometric and biochemical	Yes: Acupoint catgorial embedding therapy moxibustion produce significant reduction in bod weight insulin and HOMA-IR
Alvarado- Reynoso <sup>65</sup> Mexico City 2019	Male and Female Intervention: 42.1 ± 3.2; Control: 37.8 ± 3.3 years old.  BMI≥ 25 Kg/m²	45	Intervention: repetitive transcranial magnetic stimulation) rTMS  Control: sham rTMs	Intervention: 22, 18 Control: 23, 19	2 weeks	Primary: body weight, food craving, auto perception, general health, depression and anxiety	Yes: In the rTMS-treate group reduced body weigh anxiety, and food craving General health survedomain improved on physica functioning, emotional role and vitality. The body shap questionnaire improved.
rnandez-Lepe <sup>64</sup> Chihuahua 2019	Male  25 ± 5 years old  BMI >25 Kg/m <sup>2</sup> Sedentary	52	Intervention: spirulina maxima  Control: placebo	Intervention: 26, 26 Control: 26, 26	3 months	Primary: plasma lipid profile and antioxidant capacity	Yes: BMI, total cholestero triglycerides and LDL-decreased. HDL-C increase in all treatment group: Participants with know dyslipidemia had higher response.

Table 5. Network meta-analysis results matrix.

Matrix A: Drugs (Non-diabetic participants)								
BMI (Reference: placebo)								
DHA 470 + EPA	0.072 (-0.672,	0.143 (-0.852,	0.129 (-0.872,	-0.365 (-1.192,	-0.816 (-1.582, -0.049)			
580	0.815)	1.138)	1.130)	0.462)				
-0.072 (-0.815,	DHA 940 + EPA	0.071 (-0.927,	0.057 (-0.947,	-0.436 (-1.267,	-0.888 (-1.658, -0.117)			
0.672)	1160	1.070)	1.061)	0.394)				
-0.143 (-1.138,	-0.071 (-1.070,	Form1	-0.014 (-0.570,	-0.508 (-1.214,	-0.959 (-1.593, -0.324)			
0.852)	0.927)		0.541)	0.198)				
-0.129 (-1.130,	-0.057 (-1.061,	0.014 (-0.541,	Form2	-0.493 (-1.208,	-0.944 (-1.588, -0.301)			
0.872)	0.947)	0.570)		0.221)				
0.365 (-0.462,	0.436 (-0.394,	0.508 (-0.198,	0.493 (-0.221,	Liraglutide	-0.451 (-0.761, -0.141)			
1.192)	1.267)	1.214)	1.208)					
0.816 ( 0.049,	0.888 ( 0.117,	0.959 ( 0.324,	0.944 ( 0.301,	0.451 ( 0.141,	Plc			
1.582)	1.658)	1.593)	1.588)	0.761)				

#### Matrix B: Drugs (Diabetic participants)

Dim (Neicrenoe: metrorinin)							
Diac+Met	-0.080 (-1.307, 1.147)	-0.143 (-1.374, 1.088)	-0.774 (-2.026, 0.478)	0.124 (-1.009, 1.257)			
0.080 (-1.147,	Glim	-0.063 (-0.529, 0.403)	-0.694 (-1.404, 0.017)	0.204 (-0.266, 0.675)			
1.307)							
0.143 (-1.088,	0.063 (-0.403, 0.529)	Glim+Met	-0.631 (-1.349, 0.087)	0.267 (-0.214, 0.749)			
1.374)							
0.774 (-0.478,	0.694 (-0.017, 1.404)	0.631 (-0.087, 1.349)	Insulin	0.898 ( 0.366, 1.431)			
2.026)							
-0.124 (-1.257,	-0.204 (-0.675, 0.266)	-0.267 (-0.749, 0.214)	-0.898 (-1.431, -0.366)	Met			
1.009)		•					

Matrix A represent the estimates of the effect of treatments (standardized mean differences and 95%CI) relative to placebo. The dosage of DHA and EPA are in mg per day. Form1: D-norpseudoephedrine 50 mg, triiodothyronine 75 ug, diazepam 5 mg, atropine 0.36 mg, aloin 16.2 mg. Form2: D-norpseudoephedrine 50 mg, atropine 0.36 mg, aloin 16.2 mg. These two formulations are not approved by FDA. Plc: Placebo. Matrix B shows estimates of the effect of treatments (standardized mean differences) relative to metformin in patients with diabetes. Diac: Diacerin; Gim: Glimepiride; Met: Metformin.